

Metabolic programming and metabolic imprinting describe early life events, which impact upon on later physiological outcomes. Despite the increasing numbers of papers and studies, the distinction between metabolic programming and metabolic imprinting remains confusing. The former can be defined as a dynamic process whose effects are dependent upon a critical window(s) while the latter can be more strictly associated with imprinting at the genomic level. The clinical end points associated with these phenomena can sometimes be mechanistically explicable in terms of gene expression mediated by epigenetics. The predictivity of outcomes depends on determining if there is causality or association in the context of both early dietary exposure and future health parameters. The use of biomarkers is a key aspect of determining the predictability of later outcome, and the strengths of particular types of biomarkers need to be determined. It has become clear that several important health endpoints are impacted upon by metabolic programming/imprinting. These include the link between perinatal nutrition, nutritional epigenetics and programming at an early developmental stage and its link to a range of future health risks such as CVD and diabetes. In some cases, the evidence base remains patchy and associative, while in others, a more direct causality between early nutrition and later health is clear. In addition, it is also essential to acknowledge the communication to consumers, industry, health care providers, policy-making bodies as well as to the scientific community. In this way, both programming and, eventually, reprogramming can become effective tools to improve health through dietary intervention at specific developmental points.

Imprinting or programming as a result of early life experience is becoming an accepted scientific phenomenon. Implicit in this is the concept of a 'stage of developmental plasticity, where specific conditions give rise to later life outcomes'. The most significant aspect is metabolic imprinting, in which maternal undernutrition, obesity and diabetes during gestation and lactation can contribute towards obesity in the offspring<sup>(1)</sup>. Other endpoints that seem to be affected by early life exposure include neurodevelopment and immune modulation.

The concept of fetal growth affecting adult disease was explained by Barker<sup>(2,3)</sup> in his seminal papers. Programming later evolved to mean alterations in nutrition and growth at specific developmental points, resulting in long-term or even permanent effects<sup>(4)</sup>.

Observation is the first step and the initial link between health and early diet is often found from epidemiological investigations. One of the most exemplary studies is the Avon Longitudinal Study of Parents and Children (ALSPAC) cohort<sup>(5)</sup>. This has been the source for a host of publications in which early diet is linked to later obesity and to other health endpoints, as outlined in Table 1.

Other cohorts include the Helsinki study, which showed a link between prenatal and postnatal factors and type 2 diabetes<sup>(6)</sup>, diet in pregnancy and blood pressure of offspring<sup>(7)</sup>, maternal nutritional status and blood pressure<sup>(8)</sup> and the USA National Children's Study. This latter study is designed to examine the effects of environmental influences on the health and development of 100 000 children across the USA, following them from before birth until age 21. The goal of the study is to improve the health and well-being of children by assessing the impact of exposure on health endpoints. These and other studies are presented in more detail in section 'Nutritional epigenomics: how to make sense of what we measure'.

These and other observational studies can be misinterpreted due to confounders; however, they can help to establish associations, which can then be tested by intervention to demonstrate the causality. The observational evidence has been the starting point for the scope of review since it provides a strong suggestion of a measurable effect apparently linked to an earlier exposure. However, while numerous studies have been carried out using animal models – particularly in relation to obesity – for obvious reasons, human clinical interventions are comparatively rare.

Another crucial element in considering long-term results from early exposure is the timeframe/timing and duration of exposure. In many cases, the potential long-term effect of a single intervention is greatest in the developing system (infant or fetus), and the size of the effective dose may be relatively low. However, the ability to predict the precise effect of the intervention in terms of long-term outcome is also low. In adults, the opposite is often the case. The dietary intervention may have to be significant and the prediction of effect is immediately measurable but the long-term effect of a single intervention is low as demonstrated conceptually in Fig. 1.

A further complication is that clinical endpoints change with time and often the effects of the initial programming event may be significantly diluted by a lifetime exposure to a range of other factors. This, together with reducing metabolic plasticity and increased differentiation, may be a major factor in the lowering of programming potential as cells and organisms get older (Fig. 2).

In mechanistic terms, it has been hypothesised that fetal developmental plastic responses can cause changes in lean body mass, endocrinology, blood flow and vascular loading. These responses are then modulated or amplified in infancy and childhood and therefore lead to increased susceptibility – particularly to cardiovascular and metabolic disease – in adulthood<sup>(9)</sup>. In developmental terms, fetal exposure to a range of dietary components including Ca, folate, Mg, high or low protein and Zn as a result of maternal diet have all been, with varying degrees of confidence, associated with birth weight. Low birth weight is by itself associated with a range of long-term outcomes, including insulin resistance and type 2 diabetes in later life.

A further addition to the genre was the use of the term 'metabolic imprinting' which was adopted by Waterland & Garza<sup>(10)</sup>, who suggested that while biological mechanisms exist to 'memorise' the metabolic effects of early nutrient exposure, these were not hypothesis driven. They proposed to apply more rigour to the testing of chronic disease outcomes and on the development of biological mechanisms and the testing of hypotheses. Metabolic imprinting was defined as 'the basic biological phenomena that putatively underlie the relations among nutritional experiences of early life and later diseases'.

The authors also considered that metabolic programming, while being a useful term, did not convey with sufficient clarity the key aspects of imprinting which, as they saw it,

**Table 1.** Correlations between early exposure and later health outcomes from the Avon longitudinal study of parents and children cohort

Dietary exposure	Health endpoint	References
Infant feeding method	Obesity	Toschke <i>et al.</i> <sup>(25)</sup>
Seafood consumption in pregnancy	Neurodevelopmental outcomes	Hibbeln <i>et al.</i> and Daniels <i>et al.</i> <sup>(243,244)</sup>
Dietary energy intake at 4 months	Postnatal weight gain and childhood BMI	Ong <i>et al.</i> <sup>(245)</sup>
Insulin-like growth factor-1 levels	Intelligence quotient at 9 years	Gunnell <i>et al.</i> <sup>(246)</sup>
Prenatal paracetamol exposure	Asthma and atopy	Shaheen <i>et al.</i> <sup>(247)</sup>
Soya protein and peanut oil exposure	Peanut allergy	Lack <i>et al.</i> <sup>(248)</sup>
Early rate of weight gain	Diabetes, insulin resistance	Ong & Dunger <sup>(249)</sup>
Maternal mineral and folate intake	Bone health	Tobias <i>et al.</i> <sup>(220)</sup>

was required to encompass both susceptibility limited to a specific developmental window and a persistent effect lasting through adulthood – although it is not clear if the magnitude of the effect should be consistent through adulthood or if a falling off in potency is acceptable.

They also considered that the outcome should be specific and measurable and that a dose–response or threshold relation between a specific exposure and an outcome should be demonstrable. Waterland & Garza<sup>(10)</sup> also distinguished between other types of imprinting (e.g. hormonal and metabolic). The essence of their argument appears to be that ‘imprinting’ has particular characteristics and the term can be used in conjunction with several prefixes dependent upon the target physiological effect but that in each case there should be a mechanistic underpinning for the use of the term.

Following this suggestion, Lucas<sup>(11)</sup> raised some questions as to the use of the term ‘imprinting’. His main argument was that programming can encompass a wide range of biological effects, whereas imprinting had a much narrower range. In addition, he also felt that the use of a term more usually associated with a quite distinct event – i.e. gene imprinting, would inevitably lead to confusion. Since this early exchange, a plethora of papers have appeared which seem to use the terms imprinting and programming almost interchangeably. This is not a particularly helpful situation for communication to both scientific and non-scientific stakeholders and a robust and reliable definition is a prerequisite to developing the area.

Epigenetics, on the other hand, has been quite strictly defined in terms of specific molecular events relating to gene expression and provides a mechanistic underpinning for many imprinting/programming events. The development of clear mechanisms to explain the impact of early life exposure on later clinical endpoints would be of great value in predicting the outcomes of specific dietary interventions.


The scope of this review is to lay the foundation for the prioritisation of factors that determine the relative significance of different early exposures in terms of health outcomes. These outcomes should include both mortality and morbidity or quality of life. In this way, we can enumerate the most significant risk factors associated with the early life events and define the causality, association and effects. In particular, to provide a guide for scientists, regulators and policymakers that will enable them to understand what is presently known, prioritise the research to address the gaps and effectively impact upon public health in an understandable and targeted way. Implicit in this analysis is a realisation of the social conditions that pertain to early life exposure and later health and consequences for funding prioritisation.

## Enabling technologies and methodology

### Biomarkers – what to measure

Biological systems are constantly in a state of flux both due to internal interactions and due to external exposures. In the context of diet and health, biomarkers are factors that reflect biological status at a given time point. For example, dietary stanols and sterols will reduce cholesterol levels in hypercholesterolaemic individuals. High cholesterol is a risk factor for CVD; therefore, blood cholesterol is a biomarker which reflects the increased risk of a disease outcome and may be affected by a specific dietary intervention. Most biomarkers measure biological response at a specific time point and hence the effect of a given intervention at that time point also. Finding relevant, predictive biomarkers related to programming or imprinting is not straightforward. The biologically relevant event remains significant long after the exposure responsible for it has ceased. Finding biomarkers that are not only predictive of a later effect but which, under the best circumstances, remain measurable once the initial exposure has ceased constitutes a major problem. This will become clear when we consider definitions of biomarkers, their validation and how they can best be used.

Biomarkers have conveniently been divided into sub-categories<sup>(12)</sup>. The definitions are designed to allow for a



**Fig. 1.** Conceptual figure on the effects of exposure at different developmental ages. —, predictive power; —, intervention; —, long-term effect.




Fig. 2. The shrinking of unmodified endpoints and increase in environmentally modified endpoints over time as external factors impact through a lifetime.

simple categorisation but it also tends to describe the analytical methodology used. In addition, it also introduces the concepts of surrogate biomarkers and predictivity.

**Exposure.** A biomarker of exposure can be defined as a chemical entity (or something derived directly from it), which is measurable in an exposed individual and reflecting that exposure in a dose-dependent fashion. The simplest exposure biomarkers are the components of interest themselves. It is implicit in this type of measurement that the component is either unchanged by metabolism or can be converted into something that is directly measurable.

Since programming implies some alteration in status, exposure biomarkers are only relevant to programming if they are associated with a known and measurable effect in a time period after exposure. The measurement taken early in life may provide useful information concerning the likelihood of a subsequent health endpoint once the exposure has ceased. Observational studies such as ALSPAC in which a specific exposure is correlated with later outcomes are valuable since they can lead to the development of hypothesis-driven research. Many such studies reveal correlations rather than causal associations and this is an inherent weakness of this type of investigation. The utility of biomarkers of exposure in the context of programming is where they are linked to mechanistic or associative knowledge of the consequences of that exposure. The great advantage of developing robust biomarkers of exposure is that they are measurable events at a time when it is possible to change the outcome by dietary manipulation. A typical exposure biomarker could include the levels of dioxins whose presence in the body is reflective of earlier exposure.

**Susceptibility.** A biomarker of susceptibility has traditionally largely encompassed genetic polymorphisms or variability that give rise to an increased susceptibility to an

effect. This can be a direct (genetic) or an indirect effect. The implication is that a biomarker of genetic variability is a distinct and measurable entity in a gene which can be used to predict likely outcomes. Such genes are referred to as 'imprinted' genes.

More recently, susceptibility has grown to include epigenetic effects where there is a connection between certain genes, exposure to some environmental (including dietary) factors and later biological events. For example, folate deficiency affects epigenetic events and has been implicated in colon cancer susceptibility. This led to the conclusion that 'the portfolio of evidence from animal, human and *in vitro* studies suggests that the effects of folate deficiency and supplementation on DNA methylation are gene and site specific, and appear to depend on cell type, target organ, stage of transformation and the degree and duration of folate depletion'<sup>(13)</sup>. In these terms, susceptibility is not fixed but is measurable at a specific time. It therefore becomes a fluid and dynamic process which is affected by external factors and may change depending on when in the temporal sequence it is measured.

**Effect.** Biomarkers of effect comprise the most challenging group. In order for a biomarker of effect to be useful in the context of programming, it must fulfil some key criteria.

- (1) It should be measurable at a time point when it is able to be altered by an external (dietary) component and that alteration should be reflective of an eventual changed health endpoint. Biomarkers of effect in general may be measured at a time that is distant from the exposure and can also be as a result of cumulative exposure (e.g. DNA damage). However, in order to be relevant to programming, an effect biomarker must be predictive of a future outcome. It should be measurable before and

after the exposure event and should predict the biological outcomes.

- (2) There must be a dose-related, mechanistic rationale between exposure (and a biomarker of exposure) and the biomarker of effect and to the health endpoint. This means that many biomarkers of effect are measuring surrogate endpoints.
- (3) In common, with all biomarkers, it must be validated both in terms of analytical methodology and biological integrity.

Many of the biomarkers of effect and exposure and their relationship to eventual health outcomes have been indicated in the first instance by prospective epidemiological studies. These have suggested associations between certain events and later onset of disease. While these are certainly useful in suggesting new potential areas for study, it is important to recognise that such studies have a high tendency to being blurred by confounders, and the search for a mechanistic underpinning may be futile.

#### *Specificity of human/animal models*

Research into developmental programming of adult health and disease has made considerable progress over the past two decades but a clear consensus on the exact nutrients involved and their mechanisms remains to be established. This problem relates in part to the long-term developmental time frame in which changes in metabolism and cardiovascular function occur. At the same time, the discipline has had to contend with the dual challenges of integrating findings from lifelong epidemiological studies which have largely focussed on birth weight and its relationship (or otherwise) with adult disease and our ability to incorporate these results into appropriate nutritional intervention studies using animal models. It is now established that there are many potential influences on offspring outcome. For example, maternal body composition, age and parity, genetic constitution, macro and micronutrient intake and handling, size, shape and number of offspring, sex, type of lactation and so on.

In this section, we attempt to provide an overview of some of the major problems with both human and animal studies in conjunction with optimal experimental paradigms that may be utilised in future research aimed at elucidating the precise mechanisms by which changes in the maternal diet during reproduction can impact on the life time health of resulting offspring. Particular emphasis will be given to the applicability of the animal model that has been utilised and how similarities in the reproductive process may enable its best use in future examinations of the nutritional programming of adult health and disease.

*Human models – historical and contemporary models of developmental programming.* The majority of the early work conducted by David Barker and colleagues utilised data from historical cohorts born in the 1930s and benefited from the meticulous birth records, often kept by the same individual over long periods of time<sup>(13)</sup>. This enabled clear relationships between the size, shape and placental mass of an infant at birth with hypertension later in life<sup>(14)</sup>. Subsequently, the recruitment of long-term historical records from Finland has enabled longitudinal studies on infant

growth to be related to adult insulin sensitivity<sup>(15)</sup>. More recently, the use of nutritional interventions of preterm formula in randomised controlled studies has emphasised the impact of inappropriate growth in early infancy on later disease risk<sup>(16)</sup>. What is apparent, however, from more contemporary studies and the rise in both childhood and adult obesity is the complexity of this process and how changes in both activity and dietary intake make the translation of findings from such studies into present lifestyle interventions very difficult. At the same time, the causes of the ongoing epidemic of obesity and the predicted increase in associated renal and CVD are multifactorial<sup>(17)</sup> and these may be either exacerbated or reduced by early dietary exposure<sup>(18)</sup>.

*Critical developmental stage.* One consistent theme that is apparent from both historical and contemporary studies is that changes in nutrition at specific stages of pregnancy can have very different outcomes<sup>(19)</sup>. This is not unexpected as different organs have critical and precise developmental stages which may be compromised, or enhanced, and, thereafter, be permanently set for the rest of that individual's life. Importantly, adaptations of this type appear to be dependent not only on the period in which the mother's diet is altered but also on the diet to which she is rehabilitated<sup>(20)</sup>. One fundamental consideration is the self-limitation in food intake between early and mid gestation that occurs commonly as a result of nausea affecting approximately 90% of women in the UK that may be directly linked to Western diets<sup>(21)</sup>. The extent to which this directly relates to changes in placental function and/or fetal growth remains less clear but there is a need to match global prenatal and postnatal nutritional requirements so as to avoid accelerated growth (during pregnancy and early infant life)<sup>(22)</sup> and the concomitant increased risk of later obesity and metabolic complications<sup>(23)</sup>. Importantly, however, intergenerational acceleration mechanisms do not appear to make an important contribution to levels of childhood BMI within the population<sup>(24)</sup>.

*The lactational environment and postnatal development.* A further area requiring consideration is the relationship between the maternal diet in late pregnancy, its impact on mammary gland development and milk production and whether the infant is breast-fed or formula fed<sup>(25)</sup>. A higher macronutrient content of formula feed compared with breast milk, in conjunction with its fixed composition throughout a feed – unlike in breast-fed infants for whom milk composition changes with time – will impact on nutrient supply to the infant. It is, therefore, not only the short-term but also the long-term advantages of breast-feeding in terms of development of appetite regulation that should be considered in this regard<sup>(26)</sup>. The type of lactation also impacts on other behavioural aspects, including sleep-wake activity cycles<sup>(27)</sup>, so that extended breast-feeding may not only be beneficial in developing countries but also in developed countries<sup>(28)</sup>. Other confounding factors such as social class and smoking during pregnancy and lactation further determine postnatal diet<sup>(29)</sup>.

In summary, the relationship between nutrient supply and the key stages of development from the time of conception to weaning is highly complex and requires careful, in-depth consideration. It is necessary to conduct detailed animal experiments in a range of species in order to elucidate the mechanisms involved, be they epigenetic or related processes<sup>(30)</sup>.



*Classic animal models of nutritional programming.* The main animal models that have been utilised to date to investigate the impact of maternal diet on long-term programming have been rats and sheep<sup>(31)</sup>. These obviously have very different developmental patterns in not only the relationship between placental and fetal growth but also in maturity at birth and milk composition<sup>(32)</sup>. The advantage of using rats is their very short gestational length. However, the type of diet they consume in the wild is very different to that fed to housed laboratory animals in which semi-purified diets are the norm. Such diets provide substantially greater nutrients to pregnant rats than to controls, and thus should be considered 'pharmacological' as opposed to 'physiological' and are well outside the normal distribution. For example, in the case of high-fat diets, these contain four times as much fat compared with control diets and are at risk of being deficient in micronutrients. Not surprisingly, when fed a diet so rich in fat, maternal food intake is reduced<sup>(33)</sup>. In addition, rats exhibit coprophagia which has a substantial effect on nutrient flux and the ability to experimentally manipulate the intake of specific nutrients. It should be noted, however, that recent rodent models have been developed to overcome the issue of high fat content at the expense of other essential nutrients.

Appreciable placental growth continues up to term in the rat which is necessary in part to meet the much higher protein demands for fetal growth compared with that seen in human subjects or sheep<sup>(34)</sup>. In large mammals, the maximal period of placental growth is early in pregnancy and is normally necessary to meet the increased fetal nutrient requirements in late gestation when fetal growth is exponential<sup>(35)</sup>. Furthermore, rats produce large litters whereas sheep and human subjects normally produce only one (or two) offspring of comparable birth weight per pregnancy.

*Methodological considerations and the interpretation of metabolic programming in rat and sheep models.* There have been two major problems with rat studies with regard to assessment of the long-term cardiovascular outcomes. First, in many studies, blood pressure has only been measured using the tail-cuff technique in restrained and heated animals during the day when they are normally inactive<sup>(36)</sup>. The results with this method differ considerably from those obtained from telemetry<sup>(37)</sup>. The tail-cuff method was originally validated and recommended to use only in hypertensive animals<sup>(38)</sup>. Modest differences in blood pressure recorded in normotensive rats are not always informative, which may explain why, in more recent studies, offspring born to dams fed a low-protein/high-carbohydrate diet through pregnancy show either no difference or a reduction in blood pressure when measured using either a telemetry or an indwelling arterial catheter<sup>(39,40)</sup>. Comparable findings are seen in offspring born to dams in which food intake is reduced by 50% through pregnancy compared with controls<sup>(41)</sup>. There also appears to be a marked divergence in the long-term outcomes between sexes in rats that is primarily linked to the faster, as well as continued, growth of males compared with females<sup>(35)</sup>.

Despite the fact that sheep are ruminants, they have proved valuable in enabling us to understand the nutritional and endocrine regulation of placental-fetal development. Like in human subjects, the primary metabolic substrate for fetal metabolism is glucose, for which GLUT 1 is the main placental regulator<sup>(42)</sup>. Glucose is, thus, transported across

the placenta by active diffusion determined by its concentration in maternal blood<sup>(43)</sup>. In addition, not only does kidney development show a very similar ontogeny between sheep and human subjects, but the distribution of total nephrons across the adult population is also comparable<sup>(44)</sup>. It is also feasible to obtain very consistent blood pressure recordings in the offspring using arterial cannulation while the animal is standing freely with continual access to its diet<sup>(45)</sup>. At the same time, there is no discernable difference in blood pressure control or glucose regulation between sexes when measured in intact adult sheep<sup>(22,44)</sup>.

In summary, the use of both rats and sheep as models for examining the long-term effects of early nutritional interventions is valid and can produce consistent results. Extrapolation of these to the human situation must be carried out with care and with a clear understanding of the discrepancies of both model systems.

#### *Other models*

*Preterm infants.* Preterm-born babies may represent a human model of the third trimester of pregnancy in which the impact of the environment including nutrition can be studied. Although the precise nutritional needs of the fetus to support optimal growth velocity are not known, for instance, amino acid and long-chain PUFA (LCPUFA) supplementation have been shown to improve the early weight gain and/or body composition, respectively<sup>(46–48)</sup>. However, exposure to other environmental factors associated with being born preterm including high risk of infection and other non-nutritional factors does complicate this further.

Thus, suitable nutritional interventions may now be available that can examine the relevant short- and long-term outcomes in a consistent and validated manner to determine how contemporary diets impact on fat deposition, metabolic homeostasis and cardiovascular control in animal models. The completion of such studies may enable us to determine the optimum nutrition in terms of quantity and quality. However, as Table 2 demonstrates nutritional interventions, even to demonstrate short-term effects, must control for potential confounders and demonstrate the importance of sound intervention design in this growing field.

#### *Nutritional epigenomics: how to make sense of what we measure*

Slowing down or preventing the alarming progression of obesity worldwide represents a major public health challenge and a major health concern for future generations. The presence of a heritable or familial component of susceptibility to obesity is well established<sup>(49)</sup>. However, apart from extremely rare cases of monogenic forms, most cases correspond to a multifactorial disorder<sup>(50)</sup>. This said, however, obesity is a good example of epigenetics as these common forms are associated with a range of genetic and non-genetic familial factors, triggered by the 'developmental origins of disease' phenomenon and aggravated by environmental factors, as shown by the rate of discordance between monozygotic twins<sup>(51,52)</sup>. Epigenetic misprogramming during development is now widely thought to have a persistent effect on the

**Table 2.** Summary of studies into nutritional programming in which outcome measures are potentially confounded by a mismatch between groups in their composition of offspring from singleton and twin pregnancies

Nutritional intervention	Composition of control group	Composition of nutritionally manipulated group	Reported effect of nutritional intervention	Potential confounder	References
Maternal nutrient restriction (50% of the intake of controls) between 28 and 80 d gestation	Three singletons and six twins	Seven singletons and two twins	Raised blood pressure, increased fat mass and altered glucose handling	Significantly more singletons and fewer twins in the nutrient restricted group (All males were castrated)	Gilbert <i>et al.</i> and Ford <i>et al.</i> (250,251)
Increased maternal food intake (50% greater than controls) from 110 d gestation (term = 147 d)	Four singletons and eight twins	Seven singletons and two twins	Transient increase in food intake over the first three weeks of lactation	Significantly more singletons and fewer twins in the well fed group	Muhlhauser <i>et al.</i> (78)
Growth rate of offspring reduced by 15% between 12 and 25 weeks after birth	Seven singletons and seven twins (plus two additional groups of the same mix born to mothers nutrient restricted over the first 30 d gestation)	Three singletons and seven twins	Cardiovascular and renal dysfunction only in the group with mismatched twins and singletons	Significantly greater ratio of twin compared with singleton offspring in the intervention group. Also female offspring excluded	Cleal <i>et al.</i> (252)

health of the offspring and may even be transmitted to the next generation<sup>(53)</sup>.

The term 'epigenetics' has been defined as 'the causal interactions between genes and their products which bring phenotype into being'<sup>(54)</sup>. It is now used to refer to stably maintained mitotically (and potentially meiotically) heritable patterns of gene expression occurring without changes in DNA sequence. Mechanistically, this is achieved by a range of modifications, including DNA methylation and a complex repertoire of histone modifications: acetylation, methylation, phosphorylation, ADP ribosylation, ubiquitination leading to chromatin remodelling. These processes add to the information of the underlying genetic code conferring unique transcriptional instructions. Epigenetics instructions and machinery create a dynamic nuclear environment that specifies transcriptional states and comprises the essential components of heritable cellular memory, a hallmark of differentiation. Despite sequencing of the human genome studies of the finely tuned chromatin epigenetic networks, DNA methylation and histone modifications are required to determine how the same DNA sequence generates different cells, lineages, organs and ultimately the phenotype.

*The mechanism of epigenetic manipulation.* DNA methylation patterns and histone modifications are responsive to the environment throughout the life. The epigenetic landscapes are affected by environmental and genetic influences such as embryo culture conditions, DNA methyltransferase 1 overexpression, hyperhomocysteinaemia and folate deficiency either before or during pregnancy, in the postnatal and post-weaning period that persist into adulthood. Transient nutritional stimuli occurring at critical ontogenic stages may have long-lasting influences on expression of various genes by interacting with epigenetic mechanisms and altering the chromatin conformation and transcription factor accessibility.

Several types of sequences associated with specific epigenetic makeup are targets of a host of environmental factors that can trigger transiently or permanently disturbed chromatin architecture with altered epigenetic instructions – either at the somatic or at the germline levels – leading to aberrant patterns of gene expression.

For example,

- (1) unique genes, e.g. the glucocorticoid receptor, or, more likely, specific subsets of unique genes belonging to different pathways or systems<sup>(55,56)</sup>;
- (2) genes present as multiple copies such as of genes coding ribosomal RNA<sup>(57,58)</sup>;
- (3) whole genome epigenomic changes<sup>(59–61)</sup>.

However, still little is known about the various replication/DNA synthesis-dependent and -independent epigenetic mechanisms underlying the stochastically, genetically and environmentally triggered epigenetic changes occurring during an individual's lifetime. They may result from replication-dependent, replication-independent or DNA repair events. Most of the epigenetic changes were thought to be coupled to DNA replication. Thus, epigenetic patterns need to be faithfully maintained during each cell cycle. In addition, the maintenance of genome integrity involves specific repair pathways<sup>(62)</sup>. During the synthesis phase, this is achieved by duplication of chromatin structure in tight coordination with DNA replication. Histone synthesis and deposition onto DNA

by chromatin assembly factors ensures efficient coupling with DNA synthesis<sup>(63)</sup>. However, this faithful maintenance is not always required. Changes in epigenetic patterns are observed during the differentiation processes for several genes involved in development, cellular growth, differentiation, apoptosis or tissue- or sex-specific expression. DNA demethylation modulates mouse leptin promoter activity and the insulin-sensitive GLUT4<sup>(64)</sup> during the differentiation of 3T3-L1 cells (mouse embryonic fibroblast – adipose-like cell line)<sup>(64,65)</sup>.

*The evidence for epigenetic systems.* Recently, links have been found between circadian rhythms and major components of energy homeostasis, thermogenesis and hunger–satiety, rest–activity rhythms and the sleep–wake cycle<sup>(66,67)</sup>. The rhythmic, circadian induction of a substantial proportion of genes, by a network of clock genes, one of which is a histone acetyltransferase, by nuclear receptors and transcription factors is also controlled by chromatin remodelling. The associated circadian epigenetic patterns must be replication-independent, transient, sensitive to environmental cues and reversible. However, poorly adapted behaviour or lifestyle and desynchronised cues may disturb the modulation of gene expression. This may ultimately lead to persistence of aberrant and unphased ‘locking’ or ‘leakage’ of gene expression and unadapted responses of the organism in terms of physiology, metabolism and behaviour to environmental changes. Thus, epimutations accumulate over time, increasing the ‘epigenetic burden’ potentially leading to the onset of age- and/or environment-related diseases<sup>(68)</sup>. The life-long remodelling of our epigenomes by nutritional metabolic and behavioural factors corresponds to the new field of ‘nutritional epigenomics’.

*Trans-generational effects.* It is now widely accepted that the developmental basis of adult diseases and the non-Mendelian transmission of acquired traits cannot be attributed solely to genetic mutations or a single aetiology<sup>(69)</sup>. In addition, there is accumulating evidence that during the periconceptual, fetal and infant phases of life, exposure to environmental compounds or behaviours, placental insufficiency, maternal inadequate nutrition and metabolic disturbances can promote improper ‘epigenetic programming’, leading to susceptibility to various disease states or lesions in the first generation and sometimes subsequent generations, i.e. transgenerational effects. While developmental programming may imply an altered uterine milieu perpetuating the disease risk through the cycle of mother-to-daughter transmission, with epigenomic alterations at the somatic level, there are also examples of transmission through the germline for both sexes and with sexually dimorphic effects<sup>(70,71)</sup>. There are an increasing number of animal models, designed to mimic human conditions, that clearly involve an epigenetic and/or gene expression-based mechanism and these have recently been reviewed<sup>(72)</sup>.

DNA methylation alterations and/or histone modifications involve different types of sequences either at the somatic or at the germline levels. However, very little information is presently available to evaluate the actual impact, persistence, and dietary and therapeutic reversibility of these environmentally triggered transgenerational effects. It remains difficult to determine the conditions required for the persistence of transgenerational effects over several generations, even in the absence of the original stimulus. It also remains unclear whether the continuation of exposure over several generations

leads to ‘locked’ epigenomic patterns. If this were the case, permanently methylated cytosines, with their higher rate of mutation, would give rise to genuine genetic mutations, thereby persisting in the genome. This would have important consequences for adaptation to new environments – coping with the worldwide epidemic of obesity, for instance.

*Epigenetic studies in human subjects.* Recent studies also suggest that part of the epigenetic component can be dependent on genetic changes: there is a genetic basis for epigenetic variability between individuals, in stochastic events, susceptibility to environment/diets, to replication-dependent and replication-independent events. The finding that DNA methylation profiles can be associated with particular alleles is of considerable interest. Only a few studies in human subjects have identified associations between DNA sequence and epigenetic profiles. The present population-based approach to common diseases relates common DNA sequence variants to either disease status or incremental quantitative traits contributing to disease. This purely genetic approach is powerful and general, and Bjornsson *et al.*<sup>(73)</sup> have proposed an approach to incorporate epigenetic variation into genetic studies. Indeed, it could be that epigenetic variation (including at the epiallele and epihaplotype) may be a better predictor for risk of disease, including late onset and progressive nature of complex diseases than sequence-based approaches alone<sup>(74,75)</sup>.

*Future studies in epigenetics.* Depending on the nature and intensity of the insult, the critical spatiotemporal windows and developmental or lifelong processes involved, these epigenetic alterations can lead to permanent changes in tissue and organ structure and function; alternatively, some of the gene- and/or tissue-specific changes can be reversible by means of appropriate epigenetic tools. Given several encouraging trials, prevention and therapy of age- and lifestyle-related diseases by individualised tailoring to optimal epigenetic diets or drugs are conceivable<sup>(76,77)</sup>. However, these potential interventions will require intense efforts to unravel the complexity of these epigenetic, genetic, stochastic and environmental interactions and to evaluate their potential reversibility with minimal side effects. Given the significant and increasing proportion of women who are overweight and overfed when pregnant paying attention to the over-nourished fetus is as important as investigating the growth retarded one<sup>(78)</sup>. Improving the environment to which an individual is exposed during development may be as important as any other public health effort to enhance population health worldwide<sup>(70)</sup>. It is clear that epigenetic alterations can no longer be ignored in evaluations of the causes of obesity and its associated disorders. There is a need for systematic large-scale epigenetic studies on obesity, employing appropriate strategies and techniques and appropriately chosen environmental factors during critical spatiotemporal windows in development.

## Perinatal nutrition and CVD in adults

### Background to diet effects

The possible impact of perinatal nutrition (including both *in utero* nutrition and lactation) on the development of CVD in adulthood is a very complex issue, mainly because of the very slow evolution of the disease before clinical manifestation. The progression of fatty streaks to coronary

atherosclerosis and then to the stenosis that will provoke cardiac ischaemia or infarction may require 50 years. Moreover, the possible evolution of infarct (or hypertension) to cardiac hypertrophy and/or chronic heart failure may also require a long duration. This cardiac disease 'continuum' has been related to several risk factors, including cholesterol levels, diabetes, obesity, sedentarity, coagulation, smoking, dietary practices and vascular dysfunction. In this context, it is difficult to evaluate the possible influence of the perinatal environment, including maternal factors (genotype, nutrition, disease state including dyslipidaemia, gestational diabetes and hypertension), fetal predisposition (genotype development) and lactation. It is obviously difficult to differentiate these early putative risk factors from those which develop later independently of the link from childhood to adulthood.

#### *Epidemiological evidence of association*

**Hypertension.** Birth triggers the transition from a low blood pressure system to a high blood pressure system. Intra-uterine undernutrition is known to affect later hypertension both in experimental animals and in human subjects and the mechanism has been investigated<sup>(79)</sup>. Intra-uterine undernutrition impairs nephrogenesis and glomerular hypertrophy. These developmental alterations induce decreased filtration rate and a decreased plasma flow that will contribute to increased blood pressure. Besides this kidney functional alteration, intra-uterine undernutrition also affects the endothelium function. The mechanism involves a reduction of superoxide dismutase activity, an increase in NADPH oxidase activity and a decrease nitric oxide synthase gene expression and activity. As a consequence, nitric oxide production is reduced, whereas free radical oxygen is increased, resulting in a change in relaxation of vascular smooth muscle cells.

The quality of lactation was also shown to affect blood pressure in human subjects. Diastolic and mean blood pressure at the age 13–16 years were significantly lower in children previously fed banked breast milk compared with children fed either term or preterm infant formulas. Moreover, the authors report that the results remained unchanged after adjustment for present BMI, sex and Na intake<sup>(80)</sup>. However, this result was not confirmed in large-scale epidemiological studies. The Oxford Nutrition Survey investigated pregnant women recruited in 1942–4 to determine whether the wartime dietary rations were sufficient to prevent the deficiencies. More than 50 years later, the offspring were recruited to explore the possible impact of maternal nutrition in pregnancy on CHD risk factors, including blood pressure, but the results provided no evidence to support the hypothesis that birth weight or undernutrition in pregnancy affect hypertension<sup>(81)</sup>. Similarly, The Boyd Orr Cohort investigated a cohort of children born 1937–9 and their follow-up in 732 adults aged 65 years and this reported no evidence of the influence of breast-feeding on blood pressure<sup>(82)</sup>.

**Atherosclerosis.** The Boyd Orr Cohort, comprising 700 adults between in the years 1937 and 1939 (see above), was recently reinvestigated. The authors report that the breast-fed group displayed lower intima-media thickness of carotid arteries and a lower score in carotid and femoral

plaques<sup>(82)</sup>. The results remained unchanged after adjustment for socio-economic variables (including smoking and alcohol), and adjustment for pathway causal factors (including blood pressure, adiposity, cholesterol, insulin resistance and C-reactive protein). Atherosclerosis is considered to begin very early in life as shown in the Fate of Early Lesions in Children Study<sup>(83)</sup>. This study showed that maternal hypercholesterolaemia during pregnancy induces changes in fetal aorta that may determine the long-term susceptibility of children to fatty-streak formation and subsequent atherosclerosis. The human fetus displays arterial fatty streaks *in utero*. Although these fatty streaks regress after birth, they redevelop rapidly independently of the cholesterol status of the child. The study reports that these fatty streaks are associated with an increase in arterial wall thickness (aorta and carotids) in child than in fetus. Investigations in animals<sup>(84)</sup> showed similar results, the offspring of hypercholesterolaemic mothers displaying a significantly higher atherosclerosis lesion score at birth, at 6 months and at 12 months. Interestingly, when the mothers were treated with cholestyramine during pregnancy, the atherosclerosis lesion score in the offspring was significantly lower at birth and at 6 months and fully normalised at 12 months<sup>(81)</sup>. However, although several nutrients, including phytosterols, the SFA:PUFA ratio and *n*-3 PUFA, affect cholesterol transport in adults, the impact of these nutrients in early development has not been considered so far.

**Myocardium and coronaropathies.** The Helsinki Birth Cohort Study including more than 4000 men born 1934–4 reported a significant correlation between the ponderal index at birth (term babies only), early growth and the standardised mortality ratios for CHD<sup>(85)</sup>. Low birth weight and low ponderal index were associated with increased CHD. After 1 year of age, rapid gain in weight and BMI increased the risk of CHD in those men with a low ponderal index at birth. Epidemiological studies can be confusing. Investigations in the 'Nurses' Health Study' cohort suggested that breast-feeding may be associated with a reduction in risk of ischaemic CVD in adulthood<sup>(86)</sup>. Conversely, investigations on the 'Caerphilly study' cohort data provide little evidence of a protective influence of breast-feeding on CVD risk factors, incidence or mortality. Moreover, a possible adverse effect of breast-feeding on CHD incidence was reported, which may be related to the difficulties in differentiating the lactation effects from the individual risk factors developed after weaning<sup>(87)</sup>.

In the perinatal period, the myocardium is subjected to several key changes and some of these changes will induce a phenotype influencing cardiac function. These could be the key parameters in the pathology developed in later life such as mitochondria oxidative capacity and adrenergic regulation of cardiac function, both through membrane phospholipid homeostasis.

#### *Critical developmental stage*

The question is then restricted to the developmental stage during which the specific impact of the perinatal nutrition period on the development of CVD, independently from the known risk factors, developed during independent life. This may affect hypertension, atherosclerosis development



and localisation, individual sensitivity to ischaemia and preconditioning, occurrence and severity of infarct, development of cardiac hypertrophy and its evolution in chronic heart failure.

Several organ systems which can subsequently influence cardiovascular function via programming mechanisms have been documented in human subjects. These include the vessels (vascular compliance and endothelial function), the endocrine system (glucose and insulin metabolism), the muscles (glycolysis in exercise and insulin resistance), the kidneys (rennin–angiotensin system) and the liver (cholesterol metabolism, fibrinogen and factor VII)<sup>(88)</sup>. However, all these investigations referred specifically to perinatal dietary restriction and raise the issue of qualitative concern. Moreover, the data on the heart itself are scarce and the role of metabolic programming that may affect cardiac metabolism and function is unclear.

**Mitochondria oxidising capacity.** The transition of the cardiomyocyte energy production system from exclusive glucose oxidation to fatty acid (FA) oxidation allows the large increase in cardiac energy production capacity as required by independent life. This process is based on a large increase in mitochondria mass controlled by several key factors including mitochondrial DNA (always from maternal origin) mainly encoding for the electron transport chain, transcriptional co-activator PGC-1 $\alpha$ <sup>(89)</sup> which controls mitochondrial biogenesis, the development of FA oxidation pathways<sup>(90,91)</sup> and also cardiolipin (CL) synthesis through PPAR. Feeding dam rats a high-fat diet during pregnancy resulted in offspring which at 6 months display a significant decrease in mitochondria encoding mRNAs (mainly cytochrome oxidase subunits, dicarboxylate carrier and mitochondrial genome)<sup>(33)</sup>. CL is the key phospholipid in the function of inner mitochondrial membrane ensuring the cohesion of the electron transport chain and associated enzymes. At the cellular level, cardiac ischaemia is basically a crisis of energy production associated with an unbalanced ratio in substrate oxidation (excessive FA oxidation and decreased glucose oxidation)<sup>(92)</sup>. This unbalanced metabolism contributes to the rapid oxidation of CL which decreases in mitochondrial membranes, impairing energy production<sup>(93)</sup>. The cardiac capacity to restore CL is partly controlled by the effect of LCPUFA on PPAR, and maternal diet was reported to influence the acyl composition of CL (and hence its sensitivity to oxidation) via both FA placental transfer and breast milk<sup>(94)</sup>. However, chronic heart failure is associated to a decreased capacity of the cardiomyocytes to produce energy from FA resulting in a reduced capacity to face any increase in energy demand (the term ‘metabolic regression to fetal phenotype’ is often encountered in the literature)<sup>(91)</sup>. The efficiency of mitochondrial biogenesis and CL synthesis and the basal mitochondrial mass are key factors in cardiac pathophysiology.

**Cardiac function.** The perinatal period is also associated with the transition in the neurohumoral regulation of cardiac function to a large predominance of the  $\beta$ -adrenergic system. This system involves the internalisation of the receptor and its recycling to sarcolemma (clathrin-mediated recycling) in which phosphatidylinositol-3-kinase plays a key role. The use of  $\beta$ -blockers in the treatment of cardiac disease including coronaropathy and chronic heart failure outlines the importance of the basal  $\beta$ -adrenergic function.

The development of this pathway is based on the membrane homeostasis of phosphatidylinositol, the substrate of phosphatidylinositol-3-kinase. This enzyme is also involved in insulin signalling by triggering the translocation of GLUT4 to the membrane. The early development of the phosphatidylinositol-3-kinase pathway may thus impact on both neuro-humoral regulation of cardiac function and insulin control of cardiac metabolism, since insulin contributes to myocardium substrate balance through the regulation of AMP-activated kinase-like leptin and adiponectin.

#### *Experimental evidence and mechanistic understanding*

Several attempts have been made, using animal models, to investigate the cardiac consequences of *in utero* nutrition. The effect of maternal undernutrition during pregnancy was studied using sheep as a model system. Dong *et al.*<sup>(95)</sup> reported a change in the expression of insulin-like growth factor (IGF-1), IGF-1R and IGF-2R, in fetal myocardium associated with a ventricular enlargement in fetus. Han *et al.*<sup>(96)</sup> reported several alterations of gene expression and particularly the up-regulation for several proteins that have been linked to cardiac hypertrophy and compensatory growth in several species including human subjects. Other authors reported in the same model that maternal undernutrition decreased immunoreactive type 1 and type 2 angiotensin-II receptors (AT1 and AT2) in the left ventricle of the fetuses without affecting gene transcription of the angiotensin-II receptors or increased the transcription of mRNA for vascular endothelial growth factor, whereas immunoreactive vascular endothelial growth factor remained unchanged. All together, these data suggest a relationship between maternal undernutrition and later cardiac remodelling processes. The rat is another frequently used model. Studies have included the link between maternal dietary isoflavones and the sensitivity to dilatation and chronic heart failure of offspring, the influence of litter size on cardiac neurohumoral control, the influence of maternal nutrition on cardiomyocyte length which affects left ventricle capacity in overload and the effect of high-fat diet in mothers on mitochondrial DNA expression.

The role of specific nutrients possibly involved in metabolic imprinting of blood pressure and dietary fat has been investigated. In animal experiments (rats), Khan *et al.*<sup>(97)</sup> reported an increase in systolic and diastolic blood pressure in the adult offspring of dam fed a high-SFA diet during pregnancy. Interestingly, this increase was observed in female offspring but not in males. Investigations on the mechanism showed a significant alteration of endothelial function associated with a modified arterial lipid composition, which could result from a misbalanced SFA:PUFA ratio during early growth<sup>(98)</sup>. Such an effect of LCPUFA was also reported in children. Forsyth *et al.* compared three groups of infants fed an infant formula or the same formula supplemented with arachidonic acid and DHA or breastfed (also providing arachidonic acid and DHA). After weaning, the children were allowed to return to a non-controlled diet and re-examined 6 years later. The results showed a lower diastolic and mean blood pressure in those children who received LCPUFA during lactation either by breastfeeding or by supplementation.<sup>(99)</sup> The mechanism is still unknown but could be related with the differential effect of each

LCPUFA on blood pressure according to hypertension aetiology as reported in animal models.

### *Conclusion and future directions*

In conclusion, metabolic programming of the cardiovascular system cannot be considered yet as proven, in spite of several promising results. The range of animal investigations does not suggest a trend in the relationship between perinatal nutrition and adult cardiac function, and/or protection can be considered to be confirmed. Epidemiological studies remain unconvincing and often controversial. In addition, so far, they cover only the domains of maternal food restriction and breast-feeding. In between, there is a strong requirement for mechanistic investigations to provide science-based information on the influence of maternal diet on offspring heart function and protection from later disease. Also, these investigations will have to include the globally misbalanced dietary habits (low protein and high fat) as well as the influence of specific nutrients such as specific FA, glycaemic index, amino acids, salt and minerals, sterols or phytohormones.

### **Role of perinatal leptin in obesity risk/incidence in adults**

#### *Background to diet effects*

The incidence of obesity, defined as a BMI  $>30\text{ kg/m}^2$ , is rapidly increasing all over the world<sup>(100)</sup>. The epidemic now affects young children and accumulative evidence suggest that, in part, the origin of the disease may be influenced by fetal development and early life. Nutritional and hormonal status during pregnancy and early life could interfere irreversibly on the development of the organs involved in the control of food intake and metabolism and particularly the hypothalamic structures responsible for the establishment of the ingestive behaviour and regulation of energy expenditure.

The mechanisms responsible for this developmental programming remain poorly documented. While obesity is a multi-factorial problem and is affected by several factors, recent research indicates that the adipokine leptin plays a critical role in this programming<sup>(101)</sup>.

*Leptin sources and biological functions.* Leptin is produced essentially by the adipose tissue and its plasma levels reflect the fat reserves. There are also several extra adipose sources of leptin. The placenta in human subjects (but not in all species) produces leptin and constitutes an appreciable source of leptin for the fetus during pregnancy<sup>(102)</sup>. The mammary gland is also able to produce leptin, particularly during the early phase of lactation<sup>(103)</sup>. In addition, the mammary gland is involved in the transport of leptin from the mother to the milk, which is an additional source of leptin for the newborn<sup>(104)</sup>. The immature gastrointestinal tract may allow leptin to enter the circulation, but it is likely that leptin may have considerable effects locally and play a role in the maturation of the epithelial lining of the gut. There are leptin receptors present in the gastrointestinal tract, which suggests a localised function. Although initially there may be leptin leakage to the circulation because of gastrointestinal immaturity, access of leptin to the circulation may be limited.

Leptin is involved in an extensive number of biological functions and several isoforms of the receptor have been

identified in different organs. The best-known effects are those exerted at the hypothalamic level where the long form of the leptin receptor is predominantly expressed and exerts a pivotal role in the regulation of food intake. In peripheral organs, the short form of the leptin receptor is the dominant form expressed and its biological effects include cell proliferation and cell differentiation in adipose tissue, pancreas, liver, kidney, arteries and immune cells.

*Leptin and regulation of food intake.* At the hypothalamic level, after crossing the brain–blood barrier, leptin interacts with a complex neuronal network integrating a wide range of nervous, nutritional and hormonal signals. Leptin interacts primarily with the arcuate nucleus, where it inhibits the activity of neurons expressing orexigenic peptides (neuropeptide Y and Agouti-related protein) connected to the laterally hypothalamic nucleus which is recognised as a major controlling factor in hunger. Leptin also stimulates the activity of anorexigenic neurons expressing pro-opiomelanocortin connected to ventromedial nucleus recognised as the centre of satiety. The different hypothalamic nuclei are interconnected via a complex neuronal network with paraventricular and dorsomedial nuclei and the integration of all these stimuli determines the food intake behaviour<sup>(105)</sup>.

#### *Epidemiological evidence for association*

There is little epidemiological evidence for an association between circulating leptin and obesity. To briefly summarise, there is a rare leptin gene mutation that causes obesity in early childhood. Small-for-gestational age and preterms have lowered leptin levels. Family history of obesity has been correlated with high umbilical cord levels of leptin.

#### *Critical developmental stage*

Leptin stimulation results in a decrease in food intake, and it was initially hoped that exogenous leptin therapy might induce satiety and weight loss in the obese human. Unfortunately, it has been found that obesity is often associated with a ‘leptin resistance’, which is progressively established during ingestion of a hypercaloric diet and associated with an increase of serum leptin levels. The mechanisms underlying leptin resistance remain a matter of debate, but the two hypotheses that have received the most attention are a failure of circulating leptin to reach its target cells in the brain or a blockage of leptin signalling by activation of suppressor of signalling (SOCS3) or specific phosphatases (PTP1b). An alternative hypothesis suggests that leptin resistance may in fact be programmed during fetal and neonatal life and may be the result of an altered development of neuronal circuitry involved in food intake regulation.

The neuronal network is established during hypothalamic development occurring postnatally in rodents. In the mouse, dense neuronal fibre originating from the arcuate nucleus and reaching lateral and dorsomedian hypothalamus and paraventricular nucleus are progressively established between days 6 and 16. The development of this neuronal network occurs at the same period as a dramatic increase in leptin level occurs in the blood, the suggested origin of which is adipose tissue. This change in leptin levels is not related to food intake regulation since body weight of the animals rapidly increases

at this period. Bouret, in the group of Simerly<sup>(106,107)</sup>, clearly demonstrated that leptin at this period exerts a potent neurotrophic action. These authors have observed that *ob/ob* mice, genetically deficient in leptin, have an altered hypothalamic development characterised by a dramatic decrease in neuronal fibre density in the hypothalamic structures. Secondly, they elegantly demonstrated that leptin administration to these animals during the early postnatal period restored neuronal organisation of hypothalamic circuits in term of fibre density in the paraventricular nucleus. Finally, hypothalamic connections in the diet-induced obese rat model were shown to be permanently disrupted<sup>(108)</sup>.

#### *Experimental evidence and mechanistic understanding*

Several animal models have clearly shown that either severe undernutrition during pregnancy or placental deficiency, induce intra-uterine growth retardation (IUGR) leading to low birth weight which is associated with low leptin levels. It is also well established that the IUGR newborn show an increased susceptibility to develop obesity and metabolic syndrome when submitted to high-caloric diet during later life. One possible explanation is that leptin deficiency in IUGR causes improper programming. Supporting this hypothesis, it has been recently demonstrated<sup>(109)</sup> that neonatal leptin treatment of IUGR pups reverses developmental programming induced by mother's severe undernutrition and restores normal adult phenotype. To extend these findings to normal birth weight animals and taking advantage of the recent development of specific leptin antagonist<sup>(110)</sup>, we have recently analysed the consequences of the blockage of the postnatal leptin surge in newborn rats<sup>(111)</sup>. Leptin mutants (L39A/D40A/F41A/I42) which bind to the leptin receptor with an affinity identical to wild-type leptin, but are completely devoid of agonistic activity, have been administered during early postnatal days 2–13. Three months later, the animals were given a leptin challenge and these animals injected with the leptin antagonist early in life were leptin resistant. When a high-energy diet was given to these animals, they showed a higher susceptibility and a greater increase in body weight than control animals. At 8 months, the animals presented a higher adiposity associated with hyperleptinaemia. These data demonstrate that perinatal leptin in a normal situation plays a crucial role in the determination of the capacity of the animal to respond to leptin later in life and to protect the newborn against the adverse effect of hypercaloric diet.

Several studies have documented the evolution of leptin levels during pregnancy in normal and IUGR babies. It has been shown that leptin levels increased during late fetal life, and at birth, leptin levels are lower in IUGR babies than in normal weight newborn<sup>(112)</sup>. The chronology in the development of the different organs varies between animal species. In contrast to the rodent, the major part of neuronal development occurs before birth in the human<sup>(113)</sup>. However, it is evident that a relative neuronal plasticity remains after birth and this could be even more so in the case of IUGR, where an impairment in the development of several organs (particularly the kidney) is generally observed. As we mentioned earlier, the mammary gland is able to produce leptin and also to transfer leptin from mother's blood to milk. An interesting possibility is to consider that leptin

absorbed by the newborn via the milk may be an important factor, which participates in the final maturation of different organs such as the intestine and also hypothalamic structures involved in food intake regulation. Several studies seem to support this hypothesis. Indeed, it has been reported that breast-fed infants have higher serum leptin levels than formula-fed infants<sup>(114)</sup> and that breast-fed infants may show an decreased risk of developing obesity<sup>(115)</sup>.

Experimentally, it has been demonstrated that the intake of physiological doses of leptin during lactation in rats prevents obesity in later life<sup>(116)</sup>. All these facts support the idea that milk leptin may play a favourable role in developmental programming and constitute a credible candidate to explain, at least partially, the protective effect of breast-feeding against obesity. This is an interesting subject for future investigations. In mice, the leptin responsible for the hypothalamic development of the hypothalamic food intake circuitry is thought to be of adipose tissue origin of the newborn despite its very small quantity.

#### *Conclusions and future directions*

All the data summarised in this paper suggest that leptin constitutes a key hormonal player during the perinatal period in the prevention of unfavourable developmental programming. Additional basic research is necessary to establish the biological mechanisms involved. In addition to classical rodent models, animal models including sheep or pigs may be useful as models of the human situation. Indeed, as in human subjects, the major part of neuronal hypothalamic development occurs before birth in these two species, although it should be noted that, in the human, major synaptic proliferation occurs after birth. Epigenetic modulations are probably involved in this developmental process and the genes implicated remain to be established.

Different strategies could be envisaged to optimise the effects of leptin during developmental programming. Particular attention must be given to nutrition during pregnancy. Development of well-adapted diets associated with optimised maternal leptin levels would be beneficial.

During the postnatal period, several months of breast-feeding must be encouraged, particularly in IUGR babies. Opportunities for research on the optimisation of the postnatal diet during the critical developmental stage could potentially focus on leptin and its addition to infant formula, for instance.

### **Perinatal nutrition and type 1 diabetes in adults**

#### *Background to diet effects*

Type 1 diabetes (T1D), a chronic inflammatory disease caused by a selective destruction of the insulin-producing  $\beta$ -cells of the pancreas, is one of the most common and serious chronic diseases in children<sup>(117,118)</sup>. The incidence is increasing by 3% per year, particularly in young children and in developed countries<sup>(118)</sup>.

T1D is preceded by a pre-clinical phase characterised by autoimmunity against pancreatic islets<sup>(119)</sup>. A genetic susceptibility for developing islet autoimmunity and T1D is well documented and an environmental influence is assumed<sup>(120)</sup>.

### Epidemiological evidence for association

Over the last 15 years, several groups have initiated prospective studies from birth investigating the development of islet autoimmunity and diabetes<sup>(121–124)</sup>. These studies provide an opportunity to investigate the factors that are associated with the development of islet autoimmunity and progression to T1D. Findings from these studies have significantly contributed to our present understanding of the pathogenesis of childhood diabetes. However, the exact aetiology and pathogenesis of T1D are still unknown.

*Genetic factors influencing the development of islet autoimmunity and type 1 diabetes.* Children with a first-degree relative with T1D have a more than tenfold higher risk to develop T1D, further increasing if both parents were affected. Genetic variability in the human leucocyte antigen region explains approximately 50% of the familial clustering<sup>(125,126)</sup>; other genes have also been identified as providing more modest contributions to risk<sup>(126,127)</sup>. The concordance of T1D between monozygotic twins is up to 50%, whereas between dizygotic twins, it is only 10%<sup>(128)</sup>. Although such differences in the concordance rates between identical and non-identical twins clearly underline the impact of genes on the development of T1D, they also show that genetic susceptibility alone cannot be the ultimate cause for the disease and that environmental factors seem to modify the risk for islet autoimmunity and T1D.

*Environmental factors influencing the development of islet autoimmunity.* Prospective studies from birth have demonstrated that islet autoimmunity occurs very early in life. Around 4% of offspring of parents with T1D in the BABYDIAB (genetic risk of developing T1D) study and about 6% of genetically at-risk infants from the general population in the Finnish Diabetes Prediction and Prevention study have developed islet autoantibodies by age 2<sup>(129,130)</sup>. Children who develop autoantibodies within the first 2 years of life are those who most often develop multiple islet autoantibodies and progress to T1D in childhood<sup>(129)</sup>. These findings implicate environmental factors that are encountered before age 2 may be important for the development of islet autoimmunity. Candidate environmental factors that are suspected to influence risk for islet autoimmunity in genetically susceptible individuals are dietary factors and factors associated with maternal diabetes.

### Critical developmental stage

There are several dietary factors that are proposed to be associated with the development of islet autoimmunity and T1D but most of the research done in this field led to controversial results. There are only few prospective case-control, cohort and human-intervention studies that can be used for hypothesis testing. However, dietary factors that have already been related to the development of islet autoimmunity and T1D were examined in these following prospective studies (Fig. 3). Recently, weight gain in early life was proposed to predict the risk of islet autoimmunity in children with a first-degree relative with T1D<sup>(131)</sup>.

It has been suggested by some investigators that breast-feeding may protect against T1D<sup>(132)</sup>, whereas early introduction of supplementary milk feeding may promote




Fig. 3. Studies of the hazards ratios for risk of T1D

the development of islet autoantibodies and T1D<sup>(133)</sup>. Four prospective studies in at-risk neonates have not demonstrated an increased risk for developing islet autoantibodies in children who were not breast-fed and received cow's milk (CM) proteins early in life<sup>(134–137)</sup>. However, recent results suggest that an enhanced humoral immune response to various CM proteins in infancy is seen in a subgroup of those children who later progress to T1D. The authors imply that a dysregulated immune response to oral antigens may be an early event in the pathogenesis of T1D<sup>(138)</sup>.

Another candidate factor is the early introduction of solid food in an infant's diet. In two recent prospective studies, it was suggested that risk of development of islet autoimmunity is increased in children who were exposed to cereal proteins, and particularly gluten, early in life<sup>(139,140)</sup>. The BABYDIAB study looked at the impact of food supplementation during the first 3 months of life on the development of islet autoimmunity in offspring of parents with T1D. Children who received gluten-containing supplements during the first 3 months of life had a significantly higher risk of developing islet autoimmunity compared with children who received nongluten-containing solid food, CM-based supplements or who were breast-fed only. The Finnish Diabetes Prediction and Prevention study showed that the introduction of fruits and berries before 4 months of life was associated with a significantly higher risk of developing islet autoimmunity compared with children who received solid food supplements later in life<sup>(137)</sup>.

Dietary factors that have been proposed to protect from islet autoimmunity are vitamin D and *n*-3 fatty acids.



The prospective Dietary Autoimmunity Study in the Young showed that dietary maternal intake of vitamin D was significantly associated with a decreased risk of islet autoimmunity appearance in offspring who were at increased risk for T1D (including a dose–response effect!). Neither vitamin D intake via supplements nor the *n*-3 and *n*-6 fatty acids intake via supplements during pregnancy was associated with the appearance of islet autoimmunity in offspring<sup>(141,142)</sup>.

#### *Experimental evidence and mechanistic understanding*

There are several ongoing dietary intervention trials in newborns at high risk for T1D:

*Trial to reduce type 1 diabetes in the genetically at risk (TRIGR).* To study the impact of CM proteins in an infant's diet on the development of islet autoimmunity and T1D, an interventional trial, the trial to reduce T1D in the genetically at risk, is presently ongoing in children with increased genetic risk and who have a first-degree relative with T1D<sup>(143)</sup>. The trial has a double-blind, prospective, placebo-controlled intervention protocol, comparing casein hydrolysate with a conventional CM-based formula. The 'trial to reduce T1D in the genetically at risk' is an international multicentre study with seventy-eight clinical centres in fifteen countries. The recruitment of families for the trial to reduce T1D in the genetically at risk study was completed at the end of 2006. Altogether, 2162 children were included in the intervention study and will be followed up until the age of 10 years.

*BABYDIET.* The German-wide BABYDIET study, an interventional trial, has been initiated to investigate whether delaying dietary gluten introduction influences the development of islet autoimmunity in newborns at genetically high risk for T1D and with a first-degree relative with T1D<sup>(144)</sup>. Children participating in BABYDIET are randomised to one of two dietary intervention groups that introduce gluten-containing cereals either at age 6 months, as recommended by the German National Committee for the Promotion of Breastfeeding, or at age 12 months (intervention group). The recruitment of children was finished in 2006 and altogether 150 children have been enrolled and will be followed up until the age of 10 years. The first results are expected for 2010.

*The nutritional intervention to prevent type 1 diabetes pilot study.* The nutritional intervention to prevent type 1 diabetes study has been initiated to investigate whether DHA supplementation during pregnancy and early childhood will prevent development of islet autoimmunity in children at high genetic risk for T1D and with a family history of T1D. Eligible participants (pregnant women or infants) will be randomised to one of the two study groups: a DHA group (intervention) or a control study group substance (placebo). During pregnancy and while breast-feeding, infants will receive the study substance indirectly through their mother (either via the placenta or via the breast milk). Infants who are either partially or exclusively formula fed will receive DHA more directly through the study formula. By 6–12 months of age, all the infants will get the supplement added to solid foods. Recruitment of families for the nutritional intervention to prevent study is still ongoing.

*Maternal transfer of islet autoantibodies.* The influence of maternally transmitted islet autoantibodies on the development of islet autoimmunity and T1D has been examined both in

animal models and human subjects. In the non-obese diabetic (NOD) mouse, removal of maternally transmitted Ig prevented spontaneous diabetes in offspring mice, suggesting that maternal antibodies present during gestation including islet autoantibodies could be important factors in the pathogenesis of  $\beta$ -cell destruction<sup>(145)</sup>. Further studies in mice looking specifically at whether maternal insulin antibodies influence diabetes development reported controversial findings<sup>(146,147)</sup>.

In the BABYDIAB study, 86 % of offspring from mothers with T1D have antibodies to exogenously administered insulin at birth and 66 % of offspring have antibodies to glutamic acid decarboxylase and/or islet antigens-2A at birth. The presence or absence of maternal insulin antibodies did not affect the risk of developing diabetes-associated autoantibodies and T1D in the child, but offspring with antibodies to glutamic acid decarboxylase and/or islet antigens-2A at birth had a significantly lower diabetes risk than offspring who were autoantibody-negative at birth<sup>(148)</sup>. Therefore, and in contrast to the data from animal studies, these findings in human subjects do not support the hypothesis that fetal exposure to islet autoantibodies increases the diabetes risk, but rather suggest that fetal exposure to antibodies to glutamic acid decarboxylase and/or islet antigens-2A may protect from future endogenous islet autoimmunity and T1D. Consistent with this observation is the overall decreased risk to develop islet autoimmunity and diabetes in offspring of mothers with T1D compared with that of offspring of fathers with T1D and nondiabetic mothers<sup>(149,150)</sup>.

There is evidence that early exposure to environmental factors during pregnancy and/or early infancy influences the development of islet autoimmunity and T1D. However, the etiologic mechanisms that trigger autoimmunity and promote progression to disease are largely unknown. One major problem is that there is no access to the autoreactive T-cells within the pancreas that are responsible for the disease. Thus, we are not able to quantify and characterise these cells.

Advances in these areas are necessary if we want to fully understand the autoimmune pathogenesis of T1D. An international study (The Environmental Determinants of Diabetes in the Young), sponsored by the National Institutes of Health, is ongoing to address the early pathogenic mechanisms operating in islet autoimmunity<sup>(151)</sup>. These are long but necessary studies that we hope will provide us with the knowledge of the environmental factors that affect the disease process.

#### *Conclusions and future directions*

The link between early dietary exposure and the onset of T1D in susceptible individuals remains unproven. However, most of the investigators in the area point to the increasing incidence of T1D as evidence that the most likely causative factor is environmental rather than genetic. In most of the cases, the results of studies that pinpoint a link between early diet and the later onset of T1D have been controversial and there are a few prospective case–control, cohort and human intervention studies that can be used for hypothesis testing. The conflicting evidence may, in part, be explained by the variation in the types of genetic predisposition and in the variable populations that have been used in studies. However, the major factor that prevents meaningful studies

being carried out are the availability of biomarkers that allow researchers to detect the effects of the environment on autoimmunity and the likelihood of progression to the disease. It is the development of such environmentally responsive, pre-clinical biomarkers that will enable both mechanistic studies and improved prevention strategies to be developed. Many of the clinical advances in the treatment of T1D rely on *post hoc* interventions including islet transplantation, immune modulation and stem-cell therapy. The possibility of attempting to prevent the triggering of islet cell autodestruction or of minimising its effects until suitable therapy can be developed may act as a very useful adjunct to clinical intervention. It may also assist in preventing the onset of a second cycle of islet cell destruction after treatment.

### Perinatal nutrition and neurodevelopment

#### *Background to diet effects*

Neuroanatomical and neurophysiological studies show that brain development occurs most rapidly during fetal development and in infancy. While family influences and the external environment undoubtedly play key roles in the child's cognitive development, there is evidence that there is a certain degree of stability in a child's cognition which tracks from a very early age<sup>(152)</sup>. This suggests that early exposures possibly experienced *in utero* and postnatally may be involved in programming the brain and play a role in determining the cognitive ability.

Suboptimal cognitive ability is of considerable public health interest, because this leads to low educational attainment and these individuals tend to follow a trajectory of low socio-economic position, which is associated with fewer life chances and poorer adult health. In addition, both markers of restricted fetal growth and measures of cognition have been consistently associated with shorter life expectancy<sup>(153)</sup> and increased prevalence of psychiatric outcomes such as depression<sup>(154)</sup>, schizophrenia<sup>(154–156)</sup> and suicide<sup>(157)</sup> as well as with adult chronic disease such as heart disease<sup>(158)</sup>. A recent Scottish cohort study showed a 36% increased risk of all-cause mortality per standard deviation decrease (15 points) in childhood intelligence quotient (IQ)<sup>(159)</sup>.

#### *Epidemiological evidence for association*

Evidence that cognitive ability may at least partly be determined early in life and may be related to nutrition comes from consistent associations between measures of fetal and infant growth and neurodevelopment, with low birth weight infants experiencing delays in reaching motor milestones and tending to have lower IQ<sup>(160,161)</sup>. In the ALSPAC, a population-based birth cohort of more than 14 000 children from the South West of England, who have been followed up for 18 years, birth length was associated with a decrease in the odds of having behavioural problems at 18 months of age<sup>(162)</sup>. A recent study suggested that, in adolescents assigned either a standard or a high-nutrient diet in the postnatal weeks after term birth, the high-nutrient group had significantly higher verbal IQ and caudate volume (as measured by magnetic resonance imaging). However, it should be noted that caudate volume correlated significantly with verbal IQ in the

standard nutrient group only. The effect observed was selective to males only<sup>(163)</sup>.

*Specific nutrients.* With regard to which specific nutrients influence cognitive ability and behaviour, research has established that *n*-3 fatty acids, especially DHA which is found in abundance in the nervous system, are critical for infant growth and neurodevelopment. However, what is not clear is the effect of low levels of these nutrients on cognitive function. In ALSPAC, low seafood intake (known to contain high levels of *n*-3 fatty acids) by the mother during pregnancy was associated with an increased risk of suboptimal verbal IQ, prosocial behaviour, fine motor skills, communication skills and social development scores<sup>(164)</sup>. Furthermore, Rogers *et al.*<sup>(165)</sup> have shown that the frequency of IUGR in ALSPAC children decreased with increasing maternal fish intake – the OR of IUGR in those eating no fish was 1.85 (95% CI 1.44, 2.38) compared with those in the highest fish intake group. Higher maternal intake of oily fish in ALSPAC has also been shown to be related to the offspring's visual development<sup>(166)</sup>. Many other nutrients and micronutrients aside from *n*-3 fatty acids have been implicated in brain development and cognition. Iodine is an essential component of at least two thyroid hormones necessary for neurodevelopment, and iodine deficiency during pregnancy leads to fetal hyperthyroidism and irreversible neurological and cognitive deficits manifest as cretinism<sup>(167)</sup>. However, this may just be the tip of the iceberg, while most studies have looked at the effect of iodine supplements on cognition in socially deprived areas with low levels of iodine intake; a study carried out in 1221 school children in Spain, with iodine levels in the normal range, found that IQ was related to iodine intake<sup>(168)</sup>. A further study of 227 pregnant women in the North East of England found that approximately 40% had borderline iodine deficiency<sup>(169)</sup>. Another micronutrient that might influence cognition is Fe. Fe deficiency is the most common nutritional deficiency worldwide. A lack of sufficient Fe intake may significantly delay the development of the central nervous system because of alterations in morphology, neurochemistry and bioenergetics<sup>(170)</sup>. Several observational studies have found that children who experience anaemia early in life continue along a trajectory of poor educational performance even after the anaemia had been treated. Other micronutrients which may be important in fetal brain development are B-vitamins, including folate<sup>(171)</sup>, choline<sup>(172)</sup>, Zn<sup>(173)</sup>, vitamin D<sup>(174)</sup> and cholesterol<sup>(175)</sup>.

#### *Critical developmental stage*

*Prenatal environment.* A substantial body of work from animal models has demonstrated that imbalances in maternal nutrition during pregnancy can adversely affect normal fetal growth and neurodevelopment<sup>(176,177)</sup>. Indeed, aside from chronic exposure to tobacco smoke and alcohol, nutrition is probably the single greatest environmental influence both on the fetus and on the neonate, and plays a necessary role in the maturation and functional development of the central nervous system<sup>(178)</sup>. Inadequate nutrient availability during gestation may be related to psychiatric disease, behavioural problems, neurodevelopmental diseases, such as autism, and general cognition. In the human subjects, individuals exposed to famine *in utero* have increased risks of schizophrenia,

showing long-term consequences of prenatal diet on the brain<sup>(179,180)</sup>. Season of birth has also been shown to be associated with childhood IQ<sup>(181)</sup>, and nutrient availability could be responsible for this association. Nutrients found to be lacking in the mothers' diet could, if shown to be related to brain development, be modified to prevent disease and ensure that the child's cognitive ability is not impaired.

*Postnatal environment.* The strongest evidence for the effect of diet postnatally supports the developmental role of PUFA. Observational data from, for example, the Inuit in arctic Quebec<sup>(182)</sup> show beneficial effects on development in general. This has also been supported by clinical studies on pre- and full-term infants<sup>(183)</sup> and long-term studies on the effects of *n*-3 supplementation on visual and cognitive development throughout childhood<sup>(184)</sup>.

#### *Experimental evidence and mechanistic understanding*

*Developmental endpoints: intelligence quotient.* A key problem is that observational studies of nutrition and IQ are subject to confounding by other lifestyle factors, which co-segregate with diet. This was highlighted in a recent large prospective cohort study which examined the association between breast-feeding and IQ; the authors found that before adjustment, breast-feeding was associated with an increase of about 4 IQ points, but adjustment for maternal intelligence accounted for most of this effect and when fully adjusted for a range of relevant confounders, the association disappeared<sup>(49)</sup>. Measurement of diet is also problematic and often inaccurate due to wide exposure categories, misreporting of intake and recall bias<sup>(184)</sup>. Large, well-conducted randomised control trials (RCT) are not subject to confounding and bias and a review of RCT of infants supplemented with *n*-3 fatty acids v. unsupplemented infants showed a positive effect on visual development, although evidence for neurodevelopment is inconsistent<sup>(185)</sup>. However, most of these studies looked at infants' diet postnatally and not *in utero*. One small RCT of mothers' diet during pregnancy found that children who were born to mothers who had taken cod liver oil (*n* 48), which is high in *n*-3 fatty acids, scored higher on the Mental Processing Composite of the Kaufman Assessment Battery for Children at 4 years of age compared with children whose mothers had taken maize oil which is high in *n*-6 fatty acids (*n* 36)<sup>(186)</sup>. A study of Fe supplementation during pregnancy showed no effect on IQ at age 4, but supplementation only began at 20 weeks of pregnancy and a large proportion of children were lost to follow-up (30%)<sup>(187)</sup>. Further trial evidence is needed, but such trials would have to recruit women before becoming pregnant in order to capture early gestation. An alternative study design would be to use a Mendelian randomisation approach<sup>(188,189)</sup>. This could use the existing resources from large cohort studies to produce results more quickly and economically than an RCT and to identify more promising targets for RCT.

*Developmental endpoints: others.* Another factor that may also be relevant here in relation to cognitive, behavioural and eye development is the development of generalised movement during the first 6 months of life. This may provide a less confounded approach to map the formation of neural connections as a marker of brain development that can be determined relatively early in life, predicts neurodevelopmental outcome at

4 years and is influenced by LCPUFA status pre and postnatally in healthy term infants<sup>(190,191)</sup>.

*Mendelian randomisation as a tool for overcoming confounding.* Associations between genetic polymorphisms and phenotype are not generally subject to the problems of reverse causality, measurement error and confounding by lifestyle factors which occur in epidemiological studies<sup>(188,189,192)</sup>. The use of genes as surrogates for measuring exposures in epidemiology has been termed Mendelian randomisation and is gaining recognition as an important research tool.

Genetic polymorphisms, which affect exposure to specific nutrients by influencing the diet, altering the metabolism or cell receptor function can be used to determine whether the related nutrients are important and to elucidate the important biological pathways. One example is the 5,10-methylenetetrahydrofolate reductase enzyme which controls a rate-limiting step in the folate metabolic pathway. The T allele at the C677T polymorphic site of this gene produces a thermolabile variant, which has a reduced catalytic capacity and results in less folate being available. This common genetic variant mimics the effect of low levels of folate in the diet, and associations have been found between this polymorphism in mothers and neural tube defects<sup>(193)</sup>, which are known to be caused by low levels of folate in the diet during pregnancy. Further exploitation of this concept could highlight the extent to which components of the mothers' diet influence neurodevelopment of the child.

#### *Conclusions and future directions*

There is substantial evidence, mainly from animal studies and observational data and associations from cohort studies, that the early environment and diet play a key role in neurodevelopment. In the prenatal and early neonatal period, the greatest environmental influence on neurodevelopment is most likely nutrition and most beneficially from breast milk. Dietary influences on cognitive development during the later postnatal period are more difficult to assess from observational studies, since such effects are subject to many confounders.

Among several micronutrients studied, DHA has shown to be critical for infant growth and neurodevelopment. Sub-optimal supply of other nutrients, e.g. iodine and Fe, to fetuses and neonates might affect a range of later physiological outcomes and, in particular, neurodevelopment<sup>(166,169)</sup>.

The influence of specific nutrients, in early life, on visual development has been extensively examined. Large well-conducted RCT have demonstrated a positive effect of *n*-3 fatty acids (i.e. DHA) supplementation on visual development in infants; however, for preterm infants, data are scarce, and the evidence is less strong. A recent Cochrane review<sup>(194)</sup> suggested that early intervention programmes for preterm infants appear to have a positive effect on cognitive outcomes in the short-to-medium term; however, further studies were recommended<sup>(190)</sup>.

The use of validated early read-outs of cognitive, behavioural and visual development and the responsiveness of these to specific dietary interventions remain very relevant. General movement development during the first 6 months of life could be an important marker through which optimal neurodevelopment can be established<sup>(189,190)</sup>.



Finally, Mendelian randomisation is gaining more recognition as being an important research tool by which existing resources from large cohort studies can be used. Genetic polymorphisms could be helpful to determine whether particular nutrients are potentially important and functional in the neuro-development of the child.

## Perinatal nutrition and the atopic syndrome

### *Background to diet effects*

The atopic syndrome manifests at barrier organs of the body to the environment. Therefore, clinical conditions on the skin (prototypic disease atopic eczema), the respiratory tract (allergic rhino-conjunctivitis and bronchial asthma) and at the mucosal site of the gastrointestinal tract (food allergies) play a major role. Despite many differences in the pathogenesis of these different diseases, there is a distinct pattern of common immuno-dysregulation<sup>(195–197)</sup>. This comprises the development of chronic inflammatory disease starting out with a polarisation of T-cell effector responses towards a T-helper cell-2 phenotype. This T-helper cell-2 response controls many of the downstream effector mechanisms of allergic disease, including IgE antibody production, tissue and blood eosinophilia, mast cell activation and more.

### *Epidemiological evidence for association*

Incidence and prevalence of atopic disease are still and constantly on the rise. Particularly, in Westernised countries, about one in three children are suffering from one type or another or a combination of the above-mentioned clinical phenotypes. This phenomenon clearly indicates that environmental factors play a decisive role in increasing the immunological susceptibility for the development of this immunological dysregulation<sup>(198,199)</sup>. Despite all advances in the development of anti-inflammatory medication, there is still no primary prevention available. Furthermore, the natural cause and chronology of the disease, as exemplified by airway remodelling in asthmatic patients, cannot be prevented or disrupted with present therapy. These aspects indicate the need for better therapy and preventive measures.

### *Critical developmental stage*

Atopic children are born in a healthy state. The earliest clinical manifestation of the atopic syndrome manifests not before the first few months in life and are primarily located at the skin (atopic eczema) and the gut (food allergy). However, priming of adaptive immune responses occurs prenatally. It is now well established, for example, that antigen-specific T-cell of fetal origin is present in cord blood<sup>(200,201)</sup>. This seems to be a physiological mechanism since virtually all newborns carry these antigen-specific immune responses. They are the result of intra-uterine antigen exposure and priming.

In the development of the immuno-pathogenesis of chronic inflammatory conditions including allergies and autoimmunity, the adaptive immune system plays a very prominent role. There are subtle differences between species in terms of the development of T- and B-cell responses within the

prenatal environment. For example, in the human subjects, mature single CD4 or CD8 positive T-cells are readily detectable at about 17–20 weeks of gestation. As a consequence, antigens which pass the placental barrier can be presented to such mature and immature T-cells, leading to the development of specific T-cell immune responses. However, in mice, a species widely used for immunological research, such naïve mature T-cells, are present only 1–2 d before birth. Therefore, development of the antigen-specific T-cell repertoire mainly occurs under postnatal conditions in mice. Another example is the passage of maternal antibodies via the placental barrier. This is an active mechanism, at least partially relating to the expression of a unique type of Fc $\gamma$ -receptors – namely Fc $\gamma$ Rn which bind, uptake and release maternal antibodies to the fetal site<sup>(202,203)</sup>. The mechanism of pre and postnatal transfer varies for different Ig isotypes<sup>(204,205)</sup>. Again, there are distinct species differences which must be considered if experimental studies are designed to further explore the immuno-regulatory mechanism at this time point.

However, there is no doubt that early programming contributes to a large extent for the development of a normal state of immunological responses. This normal state is characterised by the development of clinical tolerance against self-antigens as well as harmless environmental antigens. This level of clinical tolerance depends on T-cells, is antigen specific and must be acquired and maintained throughout life<sup>(197,206,207)</sup>. Any interruption or disturbance of this physiological process will eventually lead to the development of disease. Concerning self-antigens, autoimmunity will occur; in the case of harmless environmental antigens, allergic and atopic disease will develop.

### *Experimental evidence and mechanistic understanding*

Clinical endpoints can be considered as one important set of biomarkers and are useful to distinguish sub-phenotypes such as airway inflammation, airway hyperresponsiveness, development of IgE antibody profiles. Furthermore, clinical scores (SCORAD, the clinical scoring system for atopic dermatitis) have been established and shown to be useful in observational as well as interventional studies. Another set of biomarkers are immunological endpoints. They include phenotypes and markers of the innate as well as adaptive immune system. However, particular care must be taken in terms of quality control and establishment of age- and sex-specific normal ranges. An important aspect in this regard is the assurance of inter-laboratory and inter-centre-related quality control programmes.

*Nutritional components and immune functions.* There is abundant experimental as well as epidemiological evidence that many nutritional components are able to interfere directly or indirectly with certain immune functions. Prominent examples are the consumption of fish, fish oil and margarine containing more or less well-defined levels of *n*-3/*n*-6 fatty acids<sup>(208)</sup>. One important mode of action is via interference with the formation of phospholipids which particularly play an important role in the formation of arachidonic acid and its metabolites, including PG and leukotrienes which trigger and control certain inflammatory actions. Furthermore, obesity is to a certain degree linked to leptin levels, and, in turn, leptin itself has effects on immune functions<sup>(209,210)</sup>. The same has



been shown for vitamin D<sup>(211)</sup>. Another example for immune functions, particularly in the field of inflammation, is the balance of oxidative and anti-oxidative capacities<sup>(212)</sup>. Again, this is influenced to some degree by nutritional factors, including vitamins and others.

Exposure to microbes or microbial components has also strong immuno-modulatory capacities. A prominent example in this area is the consumption of lactobacilli like *Lactobacillus rhamnosus* GG. Although the clinical benefits of prenatal and early postnatal *Lactobacillus rhamnosus* GG consumption are limited<sup>(213,214)</sup>, this approach clearly indicates that using microbes or microbial components opens an avenue for further exploration. This is also highlighted by a number of experimental studies indicating strong *in vitro* or *in vivo* (animal model systems) effects on the development of innate and adaptive immune responses<sup>(197)</sup>. In addition, prebiotics that fuel the intestinal microflora can also affect the development of the immune system<sup>(215)</sup>.

Although we have gained great insights into underlying mechanisms of nutritional and microbial immuno-modulation, particularly at early time points, we are still some way from fully understanding the effects of such interference in detail. However, such understanding is necessary to fully apply this intriguing concept to allergy prevention in human subjects. Therefore, suitable model systems must be developed for further exploration into the mechanistic fundamentals of this approach. In this regard, we have made some progress recently by designing murine models for various allergic phenotypes including acute and chronic experimental asthma with the development of airway remodelling<sup>(216)</sup>. These disease-related models emulate more closely the real situation in patients compared with the previous ones.

#### Conclusion and future directions

Development of prevention and improved intervention strategies is the major goal in the area of allergy and asthma research. The intriguing advantage of using nutritional and microbial components is the ease of safe application, particularly if applied during pregnancy, as clinical effectiveness must be paired with safety. Furthermore, the benefit of this intervention/prevention must be long lasting and causes no impairment of other types of immune responses. To develop a nutritional solution, which fulfils all of these criteria, is a major research challenge and to reach this aim, different avenues need to be explored. One approach is the molecular analysis of nutritional factors, which are associated with a reduced risk for the development of allergic disease. Another level of investigation is the establishment of a proof of concept in suitable animal models mimicking the human phenotype as closely as possible. Furthermore, it will be very important to get detailed information about the underlying mechanisms since this will result in further improvement of the preventive approach. Finally, clinical studies are required to prove the effectiveness of this approach, particularly under long-term conditions. To reach this goal, an interdisciplinary network must be established, combining the expertise of epidemiologists and clinicians, together with basic scientists from the fields of cellular biology, immunology, biochemistry and molecular biology.

## Perinatal nutrition and bone health in adults

### Background to diet effects

Osteoporosis is a major and increasing cause of morbidity and mortality in developed countries, and set to become worldwide in the next few decades. The cost of treating fragility fractures in the UK is £1.73 billion/year<sup>(217)</sup>, close to that for treating CVD (£1.75 billion)<sup>(218)</sup>. The possibility that nutritional interventions in infancy could reduce the burden of adult degenerative bone disease is therefore an important public health issue<sup>(219)</sup>. This section of the review will address three questions:

- (1) What are suitable measures or biomarkers of bone health in human subjects?
- (2) How well do these measures predict later outcome?
- (3) What are the key early factors that influence later bone health and can the effects of adverse early factors be overcome later in life?

#### *Measures or biomarkers of bone health in human subjects.*

The ideal outcome measure, osteoporotic fracture, is for obvious reasons rarely available, and bone biopsies cannot be obtained in healthy children, precluding the use of histological or histomorphometric measures. In practice, therefore, investigators are reliant on proxy measures that can be easily obtained in healthy infants and children.

Bone mass or density (BMD) is generally obtained using Dual X-ray Absorptiometry (DXA). In postmenopausal women, DXA BMD is a significant predictor of a clinical outcome, i.e. fracture risk. However, the predictive value of BMD in children is much less clear and it cannot be automatically assumed that BMD is the optimal DXA-derived parameter to use in studies examining the effects of early life factors on later bone health<sup>(220)</sup>.

Quantitative computed tomography is used to make structural bone measurements, including volumetric bone density of the peripheral skeleton (tibia and radius), quantitative computed tomography is the best compromise between the need for more detailed measures yet still with minimum radiation exposure. Radial quantitative ultrasound measurements predict fracture risk in adults<sup>(221)</sup>, independently of BMD, and may reflect aspects of bone structure not captured by DXA.

Bone is a dynamic tissue, constantly undergoing remodelling, in which resorption is followed by bone formation at the same site, allowing bone to adapt to biomechanical stresses and for old or damaged bone to be replaced. Growing bone also undergoes modelling, in which formation and resorption are uncoupled and occur at different sites, with resorption at endosteal surfaces and formation at periosteal surfaces. Bone formation and resorption can be measured using a variety of specific markers which are released into blood or urine. Markers of bone formation include osteocalcin, bone-specific alkaline phosphatase and amino-terminal procollagen propeptides of type I collagen, released at different stages of osteoblast proliferation and differentiation<sup>(222)</sup>. Markers of bone resorption are degradation products of type I collagen that can be quantified in blood – plasma carboxyterminal telopeptide I chain of type I collagen (CTX) – or urine – N-telopeptides of type-I collagen (NTX) and deoxypyridinoline normalised to creatinine. In adult

populations, and in some paediatric diseases, these markers can be useful clinical tools for monitoring the response to treatment. However, levels of bone turnover markers are influenced by many factors, including age, sex, time of day, season and pubertal stage, which makes interpretation particularly difficult in children. Furthermore, different methods and assay kits produce different values for the same marker and cannot be used interchangeably. Bone turnover markers provide a qualitative assessment of bone metabolism and may be informative when longitudinal measurements are made under standardised conditions or when comparisons can be made between randomised groups. They typically correlate poorly with measurements of bone mass in children.

#### *Epidemiological evidence for association*

Bone mass measurements during childhood have been shown to predict fracture risk over the subsequent 2 years<sup>(223)</sup> or 4 years<sup>(224)</sup>. Not surprisingly, there are no longitudinal studies relating measurements in childhood with outcome in the same individual. Nevertheless, peak bone mass is generally accepted to be a good predictor of osteoporosis risk. Using computer modelling, Hernandez *et al.*<sup>(225)</sup> predicted that a 10% increase in BMD would delay the development of osteoporosis (defined as BMD < 2.5 SD from the young adult mean) by 13 years, whereas a similar change in age at menopause or non-menopausal bone loss would only result in a delay of 2 years. There are no reliable data on the predictive value of quantitative computed tomography measurements in childhood for later outcome, but it seems reasonable to extrapolate the likely effects of observed changes in bone geometry (especially those seen in later childhood or adolescence) on bone strength to effects in later life. In contrast, it is more difficult to predict the consequences of differences in bone turnover markers in childhood for later bone health.

#### *Critical developmental stage*

A number of factors have been shown to result in increased bone mass in the short term, during the period of intervention. This may in itself have immediate outcome benefits for the individual; for example, reducing short-term fracture risk. However, to represent a potential preventative strategy against osteoporosis, any such effect must be shown to persist after the intervention has stopped, resulting in higher peak bone mass and/or favourable effects on bone structure or bone turnover. This has received much less attention.

Studies in human subjects suggest that influences in fetal life, infancy and possibly childhood may programme skeletal growth trajectory and later bone health. Data from the Southampton Women's Study suggest lower maternal fat stores, vigorous activity in late pregnancy, maternal smoking and low maternal birth weight, all predict lower neonatal bone mass<sup>(226)</sup>. Mechanistic explorations suggest the association between maternal fat stores and infant bone mass can be explained by umbilical venous leptin<sup>(227)</sup>. Both cord leptin and IGF-1<sup>(228)</sup> closely predict neonatal skeletal size. Maternal vitamin D insufficiency or deficiency (seen in 49% of women) during late pregnancy was also associated with reduced bone size and mineral mass in the offspring at 9 years<sup>(9)</sup>.

Analyses in both historical and modern prospective cohorts have shown that birth weight is positively associated with later bone mass, via an effect on body and skeletal size<sup>(229–232)</sup> and that more rapid growth during infancy and childhood is associated with higher bone mass in later life<sup>(233,234)</sup>. Weight in infancy predicts adult bone mass independently of adult lifestyle, possibly by programming of the IGF-1/growth hormone axis<sup>(234)</sup>. Importantly, data from retrospective historical cohorts suggest that differences in weight at 1 year of age predict differences in proximal femoral geometry (an independent predictor of hip strength and fracture risk) in later adult life<sup>(235)</sup> and that increased linear growth during childhood predicts a lower risk of osteoporotic fracture<sup>(236)</sup>.

#### *Experimental evidence and mechanistic understanding*

That infant nutrition could influence later bone health has also been the subject of several studies. Breast-feeding was associated with higher bone mass in children born at term<sup>(231)</sup> and our<sup>(253)</sup> data suggest a similar beneficial effect of human milk on peak bone mass in subjects born preterm. In our experimental studies, in infants randomly assigned to diet during early postnatal life, children born preterm and randomised to lower nutrient diets showed biochemical evidence of increased bone formation later in childhood<sup>(237)</sup>. In the same cohort, those who developed (usually silent) metabolic bone disease due to inadequate early intake of Ca and P were shorter at 8–12 years, suggesting adverse programming of linear growth<sup>(238)</sup>. Conversely, nutritional interventions later in childhood have less convincing long-term effects. While Ca supplementation may have short-term benefits for bone mass, these are generally lost once the intervention is withdrawn, and there is little evidence for a clinically relevant persisting effect of childhood Ca supplementation on long-term bone health<sup>(239)</sup>. There are theoretical reasons why other elements of the diet such as vitamin K, Zn, protein, Na or fruit and vegetables might influence later bone health, but very few studies have yet been conducted on specific nutrients.

Weight-bearing physical activity has attracted increasing interest as a potential modifiable determinant of peak bone mass. A number of randomised intervention studies in children and adolescents have demonstrated increased bone mass in loaded bones during the period of increased activity. Collectively, the results of these studies suggest that effects are site specific, greatest for cortical bone and that interventions may be most effective during puberty when bone growth is most rapid. Although the majority of studies have used DXA to measure bone mass, some have also reported higher cortical cross-sectional area, cortical thickness and increased parameters of bending strength, suggesting that weight-bearing exercise may have benefits for bone structure and bone mass. Follow-up of individuals who have participated in intervention trials is limited but two studies have demonstrated effects persisting after the intervention ceased on hip bone area and bone mineral content<sup>(240)</sup> and tibial periosteal circumference<sup>(241)</sup>. In some studies, the effect of weight-bearing exercise was seen only in subjects with the highest Ca intakes<sup>(241,242)</sup>.

### Conclusion and future directions

In conclusion, despite limitations in the range of available measures for assessing later bone health, there is evidence that osteoporosis risk may be at least partly modified by interventions during early life designed to optimise linear growth, nutrition and weight-bearing activity. The 'critical period' during which bone health can be programmed may well extend throughout childhood and adolescence while the skeleton is still growing. It is relevant to consider the likely practical relevance of the observed effect sizes. Later bone mass in subjects who received breast milk was about 0.4 SD higher than in those who received formula<sup>(231)</sup> – about 12% of the population variance. The effects of weight-bearing exercise interventions on BMD are in the order of 3–5%. While there are difficulties and uncertainties inherent in extrapolating bone mass data from children to adults, it has been calculated that a 2–3% increase in peak bone mass could reduce later fracture risk by 10–20%. Hence, available data suggest that the effect sizes observed with early interventions may be of a magnitude which could be potentially significant in public health terms in reducing the burden of osteoporosis.

### Conclusion

Metabolic imprinting/programming is an increasingly important concept that may prove to be the single most important mode of successful dietary intervention to improve health. While much of the effort has been concentrated towards early life (pre and early postnatal) as the most significant developmental stages, there is some evidence that, for certain health endpoints, a longer/late intervention may also be successful.

The key opportunities for interventions, which have been outlined in this review, include obesity, CVD, bone health, cognition, immune function and diabetes. These are health endpoints for which observational/epidemiological evidence for programming exists. Underpinning many of these and taking them beyond epidemiology and observational studies are the experimental intervention investigations that make use of both human and animal subjects. Providing a mechanistic basis for many of the observed effects are the epigenetic studies looking at specific molecular events that extend beyond genetic polymorphisms and provide a programmable and exquisite way of controlling gene expression and subsequent phenotype.

There remains considerable gaps in the knowledge and challenges, not least in the development of suitable systems to test hypotheses but the ultimate goal will be in the controlled and predictable beneficial manipulation of human health at all life stages in the short-term dietary interventions leading to long-term improvements in health.

### Acknowledgements

The present article has been written to reflect the presentations and discussions from the Workshop on Mechanisms and Definitions of Metabolic Imprinting, Programming and Epigenetics, organised on 5–6 June 2007 in Florence, Italy. Each author provided the scientific content for his or her respective chapter, which reflects their contribution to the

workshop. B. H. is employed by Wrigleys, M. G. by FrieslandCampina, L. H. by Mead Johnson Nutrition, K. M. by Nestlé and Dr v. D. B. by Danone. No other conflicts of interest have been declared. The work was commissioned and funded by the Metabolic Imprinting Task Force of the European branch of the International Life Sciences Institute (ILSI, Europe). Industry members of this task force are Danone, FrieslandCampina, Martek Biosciences Corporation, Mead Johnson Nutrition and Nestlé. For further information about ILSI Europe, please email [info@ilsieurope.be](mailto:info@ilsieurope.be) or call +32 2 771 00 14. The opinions expressed herein are those of the authors and do not necessarily represent the views of ILSI Europe.

### References

1. Levin BE (2006) Metabolic imprinting: critical impact of the perinatal environment on the regulation of energy homeostasis. *Philos Trans R Soc Lond B Biol Sci* **361**, 1107–1121.
2. Barker DJ (1992) The effect of nutrition of the fetus and neonate on cardiovascular disease in adult life. *Proc Nutr Soc* **51**, 135–144.
3. Barker DJ (1995) The fetal and infant origins of disease. *Eur J Clin Invest* **25**, 457–463.
4. Lucas A (1991) Programming by early nutrition in man. *Ciba Found Symp* **156**, 38–50.
5. Ness AR (2004) The Avon Longitudinal Study of Parents and Children (ALSPAC) – a resource for the study of the environmental determinants of childhood obesity. *Eur J Endocrinol* **151**, Suppl. 3, U141–U149.
6. Eriksson JG, Forsén T, Tuomilehto J, *et al.* (2003) Early adiposity rebound in childhood and risk of Type 2 diabetes in adult life. *Diabetologia* **46**, 190–194.
7. Campbell DM, Hall MH, Barker DJ, *et al.* (1996) Diet in pregnancy and the offspring's blood pressure 40 years later. *Br J Obstet Gynaecol* **103**, 273–280.
8. Godfrey KM, Forrester T, Barker DJ, *et al.* (1994) Maternal nutritional status in pregnancy and blood pressure in childhood. *Br J Obstet Gynaecol* **101**, 398–403.
9. Javadi MK, Crozier SR, Harvey NC, *et al.* (2006) Maternal vitamin D status during pregnancy and childhood bone mass at age 9 years: a longitudinal study. *Lancet* **367**, 36–43.
10. Waterland RA & Garza C (1999) Potential mechanisms of metabolic imprinting that lead to chronic disease. *Am J Clin Nutr* **69**, 179–197.
11. Lucas A (2000) Programming not metabolic imprinting. *Am J Clin Nutr* **71**, 602.
12. Branca F, Hanley AB, Pool-Zobel B, *et al.* (2001) Biomarkers in disease and health. *Br J Nutr* **86**, Suppl. 1, S55–S92.
13. Kim Y-I (2005) Nutritional epigenetics: impact of folate deficiency on DNA methylation and colon cancer susceptibility. *J Nutr* **135**, 2703–2709.
14. Barker DJ, Bull AR, Osmond C, *et al.* (1990) Fetal and placental size and risk of hypertension in adult life. *BMJ* **301**, 259–262.
15. Barker DJ, Osmond C, Forsen TJ, *et al.* (2005) Trajectories of growth among children who have coronary events as adults. *N Engl J Med* **353**, 1802–1809.
16. Singhal A (2005) Endothelial dysfunction: role in obesity-related disorders and the early origins of CVD. *Proc Nutr Soc* **64**, 15–22.
17. Keith SW, Redden DT, Katzmarzyk PT, *et al.* (2006) Putative contributors to the secular increase in obesity: exploring the roads less traveled. *Int J Obes (Lond)* **30**, 1585–1594.



18. Williams P, Kurlak LO, Perkins A, *et al.* (2007) Impaired renal function and hypertension accompany juvenile obesity: effect of prenatal diet. *Kidney Int* **72**, 279–289.
19. Symonds ME, Stephenson T, Gardner DS, *et al.* (2007) Long-term effects of nutritional programming of the embryo and fetus: mechanisms and critical windows. *Reprod Fertil Dev* **19**, 53–63.
20. Reynolds RM, Godfrey KM, Barker M, *et al.* (2007) Stress responsiveness in adult life: influence of mother's diet in late pregnancy. *J Clin Endocrinol Metab* **92**, 2208–2210.
21. Pepper G & Roberts S (2006) Rates of nausea and vomiting in pregnancy and dietary characteristics across populations. *Proc Biol Sci* **273**, 2675–2679.
22. Gardner DS, Tingey K, van Bon BWM, *et al.* (2005) Programming of glucose-insulin metabolism in adult sheep after maternal undernutrition. *Am J Physiol* **289**, R947–R954.
23. Symonds ME (2007) Integration of physiological and molecular mechanisms of the developmental origins of adult disease: new concepts and insights. *Proc Nutr Soc* **66**, 442–450.
24. Davey Smith G, Steer C, Leary S, *et al.* (2007) Is there an intra-uterine influence on obesity? Evidence from parent-child associations in ALSPAC. *Arch Dis Child* **92**, 876–880.
25. Toschke AM, Martin RM, von Kries R, *et al.* (2007) Infant feeding method and obesity: body mass index and dual-energy X-ray absorptiometry measurements at 9–10 y of age from the Avon Longitudinal Study of Parents and Children (ALSPAC). *Am J Clin Nutr* **85**, 1578–1585.
26. Sievers E, Oldigs HD, Santer R, *et al.* (2002) Feeding patterns in breast-fed and formula-fed infants. *Ann Nutr Metab* **46**, 243–248.
27. Lee K (2000) Crying and behavior pattern in breast- and formula-fed infants. *Early Hum Dev* **58**, 133–140.
28. Heird WC (2007) Progress in promoting breast-feeding, combating malnutrition, and composition and use of infant formula, 1981–2006. *J Nutr* **137**, 499S–502S.
29. Bogen DL, Hanusa BH & Whitaker RC (2004) The effect of breast-feeding with and without formula use on the risk of obesity at 4 years of age. *Obes Res* **12**, 1527–1535.
30. Symonds ME, Stephenson T, Gardner DS, *et al.* (2009) Tissue specific adaptations to nutrient supply: more than just epigenetics? *Adv Exp Med Biol* **646**, 113–118.
31. McMillen IC & Robinson JS (2005) Developmental origins of the metabolic syndrome: prediction, plasticity, and programming. *Phys Rev* **85**, 571–633.
32. Prentice AM & Prentice A (1995) Evolutionary and environmental influences on lactation. *Proc Nutr Soc* **54**, 391–400.
33. Taylor PD, McConnell J, Khan IY, *et al.* (2005) Impaired glucose homeostasis and mitochondrial abnormalities in offspring of rats fed a fat-rich diet in pregnancy. *Am J Physiol* **288**, R134–R139.
34. Widdowson EM (1950) Chemical composition of newly born animals. *Nature* **116**, 626–628.
35. Symonds ME & Gardner DS (2006) Experimental evidence for early nutritional programming of adult health in animals. *Curr Opin Nutr Metab Care* **9**, 278–283.
36. Kwong WY, Wild AE, Roberts P, *et al.* (2000) Maternal undernutrition during the preimplantation period of rat development causes blastocyst abnormalities and programming of postnatal hypertension. *Development* **127**, 4195–4202.
37. D'Angelo G, Elmarakby AA, Pollock DM, *et al.* (2005) Fructose feeding increases insulin resistance but not blood pressure in Sprague–Dawley rats. *Hypertension* **46**, 806–811.
38. Bunag RD (1973) Validation in awake rats of a tail-cuff method for measuring systolic pressure. *J Appl Physiol* **34**, 279–282.
39. Fernandez-Twinn DS, Ekizoglou S, Wayman A, *et al.* (2006) Maternal low-protein diet programs cardiac beta-adrenergic response and signaling in 3-mo-old male offspring. *Am J Physiol* **291**, R429–R436.
40. Hoppe CC, Evans RG, Moritz KM, *et al.* (2007) Combined prenatal and postnatal protein restriction influences adult kidney structure, function, and arterial pressure. *Am J Physiol* **292**, R462–R469.
41. Brennan KA, Olson DM & Symonds ME (2006) Maternal nutrient restriction alters renal development and blood pressure regulation of the offspring. *Proc Nutr Soc* **65**, 116–124.
42. Dandrea J, Wilson V, Gopalakrishnan G, *et al.* (2001) Maternal nutritional manipulation of placental growth and glucose transporter-1 abundance in sheep. *Reproduction* **122**, 793–800.
43. Edwards LJ, Symonds ME, Warnes K, *et al.* (2001) Responses of the fetal pituitary–adrenal axis to acute and chronic hypoglycaemia during late gestation in the sheep. *Endocrinology* **142**, 1778–1785.
44. Symonds ME, Budge H, Mostyn A, *et al.* (2007) Maternal diet through pregnancy – the key to future good health of the next generation? In *Nutrition Research Advances*, pp. 223–240 [SV Watkins, editor]. New York: Nova Science Publishers, Inc.
45. Gardner DS, Pearce S, Dandrea J, *et al.* (2004) Peri-implantation undernutrition programs blunted angiotensin II evoked baroreflex responses in young adult sheep. *Hypertension* **43**, 1–7.
46. Valentine CJ, Fernandez S, Rogers LK, *et al.* (2009) Early amino-acid administration improves preterm infant weight. *J Perinatol* **29**, 428–432.
47. Groh-Wargo S, Jacobs J, Auestad N, *et al.* (2005) Body composition in preterm infants who are fed long-chain polyunsaturated fatty acids: a prospective, randomized, controlled trial. *Pediatr Res* **57**, (5 Pt 1), 712–718.
48. Innis SM, Adamkin DH, Hall RT, *et al.* (2002) Docosahexaenoic acid and arachidonic acid enhance growth with no adverse effects in preterm infants fed formula. *J Pediatr* **140**, 547–554.
49. Rankinen T & Bouchard C (2006) Genetics of food intake and eating behavior phenotypes in humans. *Annu Rev Nutr* **26**, 413–434.
50. Rankinen T, Zuberi A, Chagnon YC, *et al.* (2006) The human obesity gene map: the 2005 update. *Obesity (Silver Spring)* **14**, 529–644.
51. Bouchard C, Tremblay A, Despres JP, *et al.* (1990) The response to long-term overfeeding in identical twins. *N Engl J Med* **322**, 1477–1482.
52. Fraga MF, Ballestar E, Paz MF, *et al.* (2005) Epigenetic differences arise during the lifetime of monozygotic twins. *Proc Natl Acad Sci U S A* **102**, 10604–10609.
53. Gallou-Kabani C & Junien C (2005) Nutritional epigenomics of metabolic syndrome: new perspective against the epidemic. *Diabetes* **54**, 1899–1906.
54. Waddington C (1942) Canalisation of development and inheritance of acquired characters. *Nature* **152**, 563.
55. Weaver IC, Cervoni N, Champagne FA, *et al.* (2004) Epigenetic programming by maternal behavior. *Nat Neurosci* **7**, 847–854.
56. Champagne FA, Weaver IC, Diorio J, *et al.* (2006) Maternal care associated with methylation of the estrogen receptor-alpha1b promoter and estrogen receptor-alpha expression in the medial preoptic area of female offspring. *Endocrinology* **147**, 2909–2915.
57. Santoro R (2005) The silence of the ribosomal RNA genes. *Cell Mol Life Sci* **62**, 2067–2079.
58. Oakes CC, Smiraglia DJ, Plass C, *et al.* (2003) Aging results in hypermethylation of ribosomal DNA in sperm and liver of male rats. *Proc Natl Acad Sci U S A* **100**, 1775–1780.
59. Pham TD, MacLennan NK, Chiu CT, *et al.* (2003) Uteroplacental insufficiency increases apoptosis and alters p53 gene



- methylation in the full-term IUGR rat kidney. *Am J Physiol Regul Integr Comp Physiol* **285**, R962–R970.
60. MacLennan NK, James SJ, Melnyk S, *et al.* (2004) Uteroplacental insufficiency alters DNA methylation, one-carbon metabolism, and histone acetylation in IUGR rats. *Physiol Genomics* **18**, 43–50.
  61. Pogribny IP, Ross SA, Wise C, *et al.* (2006) Irreversible global DNA hypomethylation as a key step in hepatocarcinogenesis induced by dietary methyl deficiency. *Mutat Res* **593**, 80–87.
  62. Polo SE, Roche D & Almouzni G (2006) New histone incorporation marks sites of UV repair in human cells. *Cell* **127**, 481–493.
  63. Nakatani Y, Ray-Gallet D, Quivy JP, *et al.* (2004) Two distinct nucleosome assembly pathways: dependent or independent of DNA synthesis promoted by histone H3.1 and H3.3 complexes. *Cold Spring Harb Symp Quant Biol* **69**, 273–280.
  64. Yokomori N, Tawata M & Onaya T (1999) DNA demethylation during the differentiation of 3T3-L1 cells affects the expression of the mouse GLUT4 gene. *Diabetes* **48**, 685–690.
  65. Yokomori N, Tawata M & Onaya T (2002) DNA demethylation modulates mouse leptin promoter activity during the differentiation of 3T3-L1 cells. *Diabetologia* **45**, 140–148.
  66. Staels B (2006) When the clock stops ticking, metabolic syndrome explodes. *Nat Med* **12**, 54–55.
  67. Fontaine C & Staels B (2007) The orphan nuclear receptor Rev-erb $\alpha$ : a transcriptional link between circadian rhythmicity and cardiometabolic disease. *Curr Opin Lipidol* **18**, 141–146.
  68. Issa JP (2002) Epigenetic variation and human disease. *J Nutr* **132**, Suppl. 8, 2388S–2392S.
  69. Whitelaw NC & Whitelaw E (2006) How lifetimes shape epigenotype within and across generations. *Hum Mol Genet* **15**, R131–R137.
  70. Gluckman PD, Hanson MA & Beedle AS (2007) Non-genomic transgenerational inheritance of disease risk. *Bioessays* **29**, 145–154.
  71. Yang X, Schadt EE, Wang S, *et al.* (2006) Tissue-specific expression and regulation of sexually dimorphic genes in mice. *Genome Res* **16**, 995–1004.
  72. Junien C & Nathanielsz P (2006) Report on the IASO Stock Conference: early and lifelong environmental epigenomic programming of metabolic syndrome, obesity and type II diabetes. *Obes Rev* **8**, 487–502.
  73. Bjornsson HT, Danielle Fallin M & Feinberg AP (2004) An integrated epigenetic and genetic approach to common human disease. *Trends Genet* **20**, 350–358.
  74. Abdolmaleky HM, Smith CL, Faraone SV, *et al.* (2004) Methylomics in psychiatry: modulation of gene–environment interactions may be through DNA methylation. *Am J Med Genet B Neuropsychiatr Genet* **127B**, 51–59.
  75. Petronis A (2006) Epigenetics and twins: three variations on the theme. *Trends Genet* **22**, 347–350.
  76. Egger G, Liang G, Aparicio A, *et al.* (2004) Epigenetics in human disease and prospects for epigenetic therapy. *Nature* **429**, 457–463.
  77. Ou JN, Torrisani J, Unterberger A, *et al.* (2007) Histone deacetylase inhibitor Trichostatin A induces global and gene-specific DNA demethylation in human cancer cell lines. *Biochem Pharmacol* **73**, 1297–1307.
  78. Muhlhausler BS, Adam CL, Findlay PA, *et al.* (2006) Increased maternal nutrition alters development of the appetite-regulating network in the brain. *FASEB J* **20**, 1257–1259.
  79. Franco MC, Akamine EH, Di Marco GS, *et al.* (2003) NADPH oxidase and enhanced superoxide generation in intrauterine undernourished rats: involvement of the rennin–angiotensin system. *Cardiovasc Res* **59**, 767–775.
  80. Singhal A, Cole TJ & Lucas A (2001) Early nutrition in preterm infants and later blood pressure: two cohorts after randomised trials. *Lancet* **357**, 413–419.
  81. Huxley RR & Neil HA (2004) Does maternal nutrition in pregnancy and birth weight influence levels of CHD risk factors in adult life? *Br J Nutr* **91**, 459–468.
  82. Martin RM, Ebrahim S, Griffin M, *et al.* (2005) Breastfeeding and atherosclerosis: intima-media thickness and plaques at 65-year follow-up of the Boyd Orr cohort. *Arterioscler Thromb Vasc Biol* **25**, 1482–1488.
  83. Napoli C, Glass CK, Witztum JL, *et al.* (1999) Influence of maternal hypercholesterolaemia during pregnancy on progression of early atherosclerotic lesions in childhood: Fate of Early Lesions in Children (FELIC) study. *Lancet* **354**, 1234–1241.
  84. Palinski W, D'Armiento FP, Witztum JL, *et al.* (2001) Maternal hypercholesterolemia and treatment during pregnancy influence the long-term progression of atherosclerosis in offspring of rabbits. *Circ Res* **89**, 991–996.
  85. Eriksson JG, Forsen T, Tuomilehto J, *et al.* (2001) Early growth and coronary heart disease in later life: longitudinal study. *BMJ* **322**, 949–953.
  86. Rich-Edwards JW, Stampfer MJ, Manson JE, *et al.* (2004) Breastfeeding during infancy and the risk of cardiovascular disease in adulthood. *Epidemiology* **15**, 550–556.
  87. Martin RM, Ben-Shlomo Y, Gunnell D, *et al.* (2005) Breast feeding and cardiovascular disease risk factors, incidence, and mortality: the Caerphilly study. *J Epidemiol Commun Health* **59**, 121–129.
  88. Godfrey KM & Barker DJ (2000) Fetal nutrition and adult disease. *Am J Clin Nutr* **71**, Suppl. 5, 1344S–1352S.
  89. McLeod CJ, Pagel I & Sack MN (2005) The mitochondrial biogenesis regulatory program in cardiac adaptation to ischemia – a putative target for therapeutic intervention. *Trends Cardiovasc Med* **15**, 118–123.
  90. Huss JM & Kelly DP (2004) Nuclear receptor signaling and cardiac energetics. *Circ Res* **95**, 568–578.
  91. Huss JM & Kelly DP (2005) Mitochondrial energy metabolism in heart failure: a question of balance. *J Clin Invest* **115**, 547–555.
  92. Grynberg A (2005) Effectors of fatty acid oxidation reduction: promising new anti-ischaemic agents. *Curr Pharm Des* **11**, 489–509.
  93. Paradies G, Petrosillo G, Pistolese M, *et al.* (2004) Decrease in mitochondrial complex I activity in ischemic/reperfused rat heart: involvement of reactive oxygen species and cardiolipin. *Circ Res* **94**, 53–59.
  94. Berger A, Gershwin ME & German JB (1992) Effects of various dietary fats on cardiolipin acyl composition during ontogeny of mice. *Lipids* **27**, 605–612.
  95. Dong F, Ford SP, Fang CX, *et al.* (2005) Maternal nutrient restriction during early to mid gestation up-regulates cardiac insulin-like growth factor (IGF) receptors associated with enlarged ventricular size in fetal sheep. *Growth Horm IGF Res* **15**, 291–299.
  96. Han HC, Austin KJ, Nathanielsz PW, *et al.* (2004) Maternal nutrient restriction alters gene expression in the ovine fetal heart. *J Physiol* **558**, (Pt 1), 111–121.
  97. Khan IY, Taylor PD, Dekou V, *et al.* (2003) Gender-linked hypertension in offspring of lard-fed pregnant rats. *Hypertension* **41**, 168–175.
  98. Ghosh P, Bitsanis D, Ghebremeskel K, *et al.* (2001) Abnormal aortic fatty acid composition and small artery function in offspring of rats fed a high fat diet in pregnancy. *J Physiol* **533**, 815–822.
  99. Forsyth JS, Willatts P, Agostoni C, *et al.* (2003) Long chain polyunsaturated fatty acid supplementation in infant formula

- and blood pressure in later childhood: follow up of a randomised controlled trial. *BMJ* **326**, 953.
100. Rodgers A, Vaughan P, Prentice T, *et al.* (2002) *The World Health Report: Reducing Risks, Promoting Healthy Life*. Geneva: World Health Organisation.
  101. Cottrell EC & Ozanne SE (2007) Developmental programming of energy balance and the metabolic syndrome. *Proc Nutr Soc* **66**, 198–206.
  102. Laivuori H, Gallaher MJ, Collura L, *et al.* (2006) Relationships between maternal plasma leptin, placental leptin mRNA and protein in normal pregnancy, pre-eclampsia and intrauterine growth restriction without pre-eclampsia. *Mol Hum Reprod* **12**, 551–556.
  103. Smith-Kirwin SM, O'Connor DM, De Johnston J, *et al.* (1998) Leptin expression in human mammary epithelial cells and breast milk. *J Clin Endocrinol Metab* **83**, 1810–1813.
  104. Uysal FK, Onal EE, Aral YZ, *et al.* (2002) Breast milk leptin: its relationship to maternal and infant adiposity. *Clin Nutr* **21**, 157–160.
  105. Friedman JM & Halaas JL (1998) Leptin and the regulation of body weight in mammals. *Nature* **395**, 763–770.
  106. Bouret SG, Draper SJ & Simerly RB (2004) Trophic action of leptin on hypothalamic neurons that regulate feeding. *Science* **304**, 108–110.
  107. Bouret SG & Simerly RB (2006) Developmental programming of hypothalamic feeding circuits. *Clin Genet* **70**, 295–301. Review.
  108. Bouret SG, Gorski JN, Patterson CM, *et al.* (2008) Hypothalamic neural projections are permanently disrupted in diet-induced obese rats. *Cell Metab* **7**, 179–185.
  109. Vickers MH, Gluckman PD, Coveny AH, *et al.* (2005) Neonatal leptin treatment reverses developmental programming. *Endocrinology* **146**, 4211–4216.
  110. Solomon G, Niv-Spector L, Gonen-Berger D, *et al.* (2006) Preparation of leptin antagonists by site-directed mutagenesis of human, ovine, rat, and mouse leptin's site III: implications on blocking undesired leptin action *in vivo*. *Ann N Y Acad Sci* **1091**, 531–539.
  111. Attig L, Solomon G & Taouis M, *et al.* (2007) Early postnatal leptin blockage induces a long term leptin resistance in rats. Pre-congress satellite meeting on 'Early Nutrition Programming and health outcomes in later life', European Congress on Obesity, Budapest.
  112. Jaquet D, Leger J, Levy-Marchal C, *et al.* (1998) Ontogeny of leptin in human fetuses and newborns: effect of intrauterine growth retardation on serum leptin concentrations. *J Clin Endocrinol Metab* **83**, 1243–1246.
  113. Grayson BE, Allen SE, Billes SK, *et al.* (2006) Prenatal development of hypothalamic neuropeptide systems in the non-human primate. *Neuroscience* **143**, 975–986.
  114. Savino F, Nanni GE, Maccario S, *et al.* (2004) Breast-fed infants have higher leptin values than formula-fed infants in the first four months of life. *J Pediatr Endocrinol Metab* **17**, 1527–1532.
  115. von Kries R, Koletzko B, Sauerwald T, *et al.* (1999) Breast feeding and obesity: cross-sectional study. *BMJ* **17**, 147–150.
  116. Pico C, Oliver P, Sanchez J, *et al.* (2007) The intake of physiological doses of leptin during lactation in rats prevents obesity in later life. *Int J Obes (Lond)* **31**, 1199–1209.
  117. Green A & Patterson CC (2001) Trends in the incidence of childhood-onset diabetes in Europe 1989–1998. *Diabetologia* **44** Suppl. 3, B3–B8.
  118. Onkamo P, Vaananen S, Karvonen M, *et al.* (1999) Worldwide increase in incidence of Type I diabetes – the analysis of the data on published incidence trends. *Diabetologia* **42**, 1395–1403.
  119. Eisenbarth GS (1986) Type I diabetes mellitus. A chronic autoimmune disease. *N Engl J Med* **314**, 1360–1368.
  120. Atkinson MA & Eisenbarth GS (2001) Type 1 diabetes: new perspectives on disease pathogenesis and treatment. *Lancet* **358**, 221–229.
  121. Ziegler AG, Hillebrand B, Rabl W, *et al.* (1993) On the appearance of islet associated autoimmunity in offspring of diabetic mothers: a prospective study from birth. *Diabetologia* **36**, 402–408.
  122. Kupila A, Muona P, Simell T, *et al.* (2001) Feasibility of genetic and immunological prediction of type I diabetes in a population-based birth cohort. *Diabetologia* **44**, 290–297.
  123. Rewers M, Bugawan TL, Norris JM, *et al.* (1996) Newborn screening for HLA markers associated with IDDM: diabetes autoimmunity study in the young (DAISY). *Diabetologia* **39**, 807–812.
  124. Honeyman MC, Coulson BS, Stone NL, *et al.* (2000) Association between rotavirus infection and pancreatic islet autoimmunity in children at risk of developing type 1 diabetes. *Diabetes* **49**, 1319–1324.
  125. Risch N (1989) Genetics of IDDM: evidence for complex inheritance with HLA. *Genet Epidemiol* **6**, 143–148.
  126. Davies JL, Kawaguchi Y, Bennett ST, *et al.* (1994) A genome-wide search for human type 1 diabetes susceptibility genes. *Nature* **371**, 130–136.
  127. Cox NJ, Wapelhorst B, Morrison VA, *et al.* (2001) Seven regions of the genome show evidence of linkage to type 1 diabetes in a consensus analysis of 767 multiplex families. *Am J Hum Genet* **69**, 820–830.
  128. Kyvik KO, Green A & Beck-Nielsen H (1995) Concordance rates of insulin dependent diabetes mellitus: a population based study of young Danish twins. *BMJ* **311**, 913–917.
  129. Hummel M, Bonifacio E, Schmid S, *et al.* (2004) Brief communication: early appearance of islet autoantibodies predicts childhood type 1 diabetes in offspring of diabetic parents. *Ann Intern Med* **140**, 882–886.
  130. Kimpimaki T, Kulmala P, Savola K, *et al.* (2002) Natural history of beta-cell autoimmunity in young children with increased genetic susceptibility to type 1 diabetes recruited from the general population. *J Clin Endocrinol Metab* **87**, 4572–4579.
  131. Couper JJ, Beresford S, Hirte C, *et al.* (2009) Weight gain in early life predicts risk of islet autoimmunity in children with first degree relative with type 1 diabetes. *Diabetes Care* **32**, 94–99.
  132. Sadauskaite-Kuehne V, Ludvigsson J, Padaiga Z, *et al.* (2004) Longer breastfeeding is an independent protective factor against development of type 1 diabetes mellitus in childhood. *Diabetes Metab Res Rev* **20**, 150–157.
  133. Vaarala O, Knip M, Paronen J, *et al.* (1999) Cow's milk formula feeding induces primary immunization to insulin in infants at genetic risk for type 1 diabetes. *Diabetes* **48**, 1389–1394.
  134. Couper JJ, Steele C, Beresford S, *et al.* (1999) Lack of association between duration of breast-feeding or introduction of cow's milk and development of islet autoimmunity. *Diabetes* **48**, 2145–2149.
  135. Norris JM, Beaty B, Klingensmith G, *et al.* (1996) Lack of association between early exposures to cow's milk protein and beta-cell autoimmunity. Diabetes Autoimmunity Study in the Young (DAISY). *JAMA* **276**, 609–614.
  136. Hummel M, Fuchtenbusch M, Schenker M, *et al.* (2000) No major association of breast-feeding, vaccinations, and childhood viral diseases with early islet autoimmunity in the German BABYDIAB Study. *Diabetes Care* **23**, 969–974.
  137. Virtanen SM, Kenward MG, Erkkola M, *et al.* (2006) Age at introduction of new foods and advanced beta cell autoimmunity in young children with HLA-conferred susceptibility to type 1 diabetes. *Diabetologia* **49**, 1512–1521.

138. Lupopajarvi K, Savilahti E, Virtanen SM, *et al.* (2008) Enhanced levels of cow's milk antibodies in infancy in children who develop type 1 diabetes later in childhood. *Pediatr Diabetes* **9**, 434–441.
139. Ziegler AG, Schmid S, Huber D, *et al.* (2003) Early infant feeding and risk of developing type 1 diabetes-associated autoantibodies. *JAMA* **290**, 1721–1728.
140. Norris JM, Barriga K, Klingensmith G, *et al.* (2003) Timing of initial cereal exposure in infancy and risk of islet autoimmunity. *JAMA* **290**, 1713–1720.
141. Fronczak CM, Barón AE, Chase HP, *et al.* (2003) *In utero* dietary exposures and risk of islet autoimmunity in children. *Diabetes Care* **26**, 3237–3242.
142. Zippiti CS & Akobeng AK (2008) Supplementation in early childhood and risk of type 1 diabetes: a systematic review and meta-analysis. *Arch Dis Child* **93**, 512–517.
143. Sadeharju K, Hamalainen AM, Knip M, *et al.* (2003) Enterovirus infections as a risk factor for type I diabetes: virus analyses in a dietary intervention trial. *Clin Exp Immunol* **132**, 271–277.
144. Schmid S, Buuck D, Knopff A, *et al.* (2004) BABYDIET, a feasibility study to prevent the appearance of islet autoantibodies in relatives of patients with Type 1 diabetes by delaying exposure to gluten. *Diabetologia* **47**, 1130–1131.
145. Greeley SA, Katsumata M, Yu L, *et al.* (2002) Elimination of maternally transmitted autoantibodies prevents diabetes in non-obese diabetic mice. *Nat Med* **8**, 399–402.
146. Koczwara K, Ziegler AG & Bonifacio E (2004) Maternal immunity to insulin does not affect diabetes risk in progeny of non obese diabetic mice. *Clin Exp Immunol* **136**, 56–59.
147. Melanitou E, Devendra D, Liu E, *et al.* (2004) Early and quantal (by litter) expression of insulin autoantibodies in the nonobese diabetic mice predict early diabetes onset. *J Immunol* **173**, 6603–6610.
148. Koczwara K, Bonifacio E & Ziegler AG (2004) Transmission of maternal islet antibodies and risk of autoimmune diabetes in offspring of mothers with type 1 diabetes. *Diabetes* **53**, 1–4.
149. Warram JH, Krolewski AS, Gottlieb MS, *et al.* (1984) Differences in risk of insulin-dependent diabetes in offspring of diabetic mothers and diabetic fathers. *N Engl J Med* **311**, 149–152.
150. Pociot F, Norgaard K, Hobolth N, *et al.* (1993) A nationwide population-based study of the familial aggregation of type 1 (insulin-dependent) diabetes mellitus in Denmark. Danish Study Group of Diabetes in Childhood. *Diabetologia* **36**, 870–875.
151. TEDDY investigators (USA – Denver Augusta/Gainesville, Seattle, Tampa; Germany – Munich; Finland – Turku, Tampere, Oulu; Sweden – Malmö) (2004) The environmental determinants of diabetes in the young study (Abstract). In Programme and Abstracts. Cambridge: Immunology of Diabetes Society Conference, p. 160.
152. Bornstein MH, Hahn CS, Bell C, *et al.* (2006) Stability in cognition across childhood: a developmental cascade. *Psychol Sci* **17**, 151–158.
153. Batty GD, Deary IJ & Gottfredson LS (2007) Pre-morbid (early life) IQ and later mortality risk: systematic review. *Ann Epidemiol* **17**, 278–288.
154. Zammit S, Allebeck P, David AS, *et al.* (2004) Longitudinal study of premorbid IQ Score and risk of developing schizophrenia, bipolar disorder, severe depression, and other nonaffective psychoses. *Arch Gen Psychiatry* **61**, 354–360.
155. Gunnell D, Harrison G, Whitley E, *et al.* (2005) The association of fetal and childhood growth with risk of schizophrenia. Cohort study of 720,000 Swedish men and women. *Schizophr Res* **79**, 315–322.
156. Osler M, Lawlor DA & Nordentoft M (2007) Cognitive function in childhood and early adulthood and hospital admission for schizophrenia in Danish men born in 1953. *Schizophr Res* **92**, 132–141.
157. Mittendorfer-Rutz E, Rasmussen F & Wasserman D (2004) Restricted fetal growth and adverse maternal psychosocial and socioeconomic conditions as risk factors for suicidal behaviour of offspring: a cohort study. *Lancet* **364**, 1135–1140.
158. Batty GD & Deary IJ (2004) Early life intelligence and adult health. *BMJ* **329**, 585–586.
159. Hart CL, Taylor MD, Smith GD, *et al.* (2005) Childhood IQ and all-cause mortality before and after age 65: prospective observational study linking the Scottish Mental Survey 1932 and the Midspan studies. *Br J Health Psychol* **10**, 153–165.
160. Shenkin SD, Starr JM, Pattie A, *et al.* (2001) Birth weight and cognitive function at age 11 years: the Scottish Mental Survey 1932. *Arch Dis Child* **85**, 189–197.
161. Richards M, Hardy R, Kuh D, *et al.* (2001) Birth weight and cognitive function in the British 1946 birth cohort: longitudinal population-based study. *BMJ* **322**, 199–203.
162. Wiles NJ, Peters TJ, Heron J, *et al.* (1996) Fetal growth and behavioural problems: results from the ALSPAC cohort. *Am J Epidemiol* **163**, 829–837.
163. Isaacs EB, Gadian DG, Sabatini S, *et al.* (2008) The effect of early human diet on caudate volumes and IQ. *Pediatr Res* **63**, 308–314.
164. Hibbeln JR, Davis JM, Steer C, *et al.* (2007) Maternal seafood consumption in pregnancy and neurodevelopment outcomes in childhood (ALSPAC study): an observational cohort study. *Lancet* **369**, 578–585.
165. Rogers I, Emmett P, Baker D, *et al.* (1998) Financial difficulties, smoking habits, composition of the diet and birthweight in a population of pregnant women in the South West of England. ALSPAC Study Team. Avon Longitudinal Study of Pregnancy and Childhood. *Eur J Clin Nutr* **52**, 251–260.
166. Williams C, Birch EE, Emmett PM, *et al.* (2001) Avon Longitudinal Study of Pregnancy and Childhood Study Team. Stereoacuity at age 3-5 y in children born full-term is associated with prenatal and postnatal dietary factors: a report from a population-based cohort study. *Am J Clin Nutr* **73**, 316–322.
167. Black RE (2001) Micronutrients in pregnancy. *Br J Nutr* **85**, S193–S197.
168. Santiago-Fernandez P, Torres-Barahona R, Muela-Martinez JA, *et al.* (2004) Intelligence quotient and iodine intake: a cross-sectional study in children. *J Clin Endocrinol Metab* **89**, 3851–3857.
169. Kibirige MS, Hutchison S, Owen CJ, *et al.* (2004) Prevalence of maternal dietary iodine insufficiency in the north east of England: implications for the fetus. *Arch Dis Child Fetal Neonatal Ed* **89**, F436–F439.
170. Beard J (2007) Recent evidence from human and animal studies regarding iron status and infant development. *J Nutr* **137**, 524S–530S.
171. Blaise SA, Nedelec E, Schroeder H, *et al.* (2007) Gestational vitamin B deficiency leads to homocysteine-associated brain apoptosis and alters neurobehavioral development in rats. *Am J Pathol* **170**, 667–679.
172. Zeisel SH (2006) The fetal origins of memory: the role of dietary choline in optimal brain development. *J Pediatr* **149**, S131–S136.
173. Bhatnagar S & Taneja S (2001) Zinc and cognitive development. *Br J Nutr* **85**, S139–S145.
174. McGrath JJ, Feron FP, Burne TH, *et al.* (2004) Vitamin D<sub>3</sub>-implications for brain development. *J Steroid Biochem Mol Biol* **89–90**, 557–560.
175. Herz J & Chen Y (2006) Reelin, lipoprotein receptors and synaptic plasticity. *Nat Rev Neurosci* **7**, 850–859.
176. Perry I (1997) Fetal growth and development: the role of nutrition and other factors. In *A lifecourse approach to chronic*



- disease epidemiology, pp. 145–168 [D Kuh and Y Ben Shlomo, editors]. Oxford: OUP.
177. Lucas A (1998) Programming by early nutrition: an experimental approach. *J Nutr* **128**, 401S–406S.
  178. Morgane PJ, Austin-LaFrance R, Bronzino J, *et al.* (1993) Prenatal malnutrition and development of the brain. *Neurosci Biobehav Rev* **17**, 91–128.
  179. Susser E, Hoek HW & Brown A (1998) Neurodevelopmental disorders after prenatal famine: the story of the Dutch Famine Study. *Am J Epidemiol* **147**, 213–216.
  180. McClellan JM, Susser E & King MC (2006) Maternal famine, *de novo* mutations, and schizophrenia. *JAMA* **296**, 582–584.
  181. Lawlor DA, Ronalds G, Clarke H, *et al.* (2006) Season of birth and childhood intelligence: findings from the Aberdeen Children of the 1950s cohort study. *Br J Educ Psychol* **76**, 481–499.
  182. Jacobson JL, Jacobson SW, Muckle G, *et al.* (2008) Beneficial effects of a polyunsaturated fatty acid on infant development: evidence from the Inuit of Arctic Quebec. *J Pediatr* **152**, 356–364.
  183. Fleith M & Clandinin MT (2005) Dietary PUFA for preterm and term infants: review of clinical studies. *Crit Rev Food Sci Nutr* **45**, 205–229. Review.
  184. Eilander A, Hundscheid DC, Osendarp SJ, *et al.* (2007) Effects of *n*-3 long chain polyunsaturated fatty acid supplementation on visual and cognitive development throughout childhood: a review of human studies. *Prostaglandins Leukot Essent Fatty Acids* **76**, 189–203. Review.
  185. McCann JC & Ames BN (2005) Is docosahexaenoic acid, an *n*-3 long-chain polyunsaturated fatty acid, required for development of normal brain function? An overview of evidence from cognitive and behavioral tests in humans and animals. *Am J Clin Nutr* **82**, 281–295.
  186. Helland IB, Smith L, Saarem K, *et al.* (2003) Maternal supplementation with very-long-chain *n*-3 fatty acids during pregnancy and lactation augments children's IQ at 4 years of age. *Pediatrics* **111**, e39–e44.
  187. Zhou SJ, Gibson RA, Crowther CA, *et al.* (2006) Effect of iron supplementation during pregnancy on the intelligence quotient and behavior of children at 4 y of age: long-term follow-up of a randomized controlled trial. *Am J Clin Nutr* **83**, 1112–1117.
  188. Davey Smith G & Ebrahim S (2005) What can mendelian randomisation tell us about modifiable behavioural and environmental exposures? *BMJ* **330**, 1076–1079.
  189. Davey Smith G & Ebrahim S (2004) Mendelian randomization: prospects, potentials, and limitations. *Int J Epidemiol* **33**, 30–42.
  190. Bouwstra H, Dijck-Brouwer DA, Wildeman JA, *et al.* (2003) Long-chain polyunsaturated fatty acids have a positive effect on the quality of general movements of healthy term infants. *Am J Clin Nutr* **78**, 313–318.
  191. Smithers LG, Gibson RA, McPhee A, *et al.* (2008) Effect of long-chain polyunsaturated fatty acid supplementation of preterm infants on disease risk and neurodevelopment: a systematic review of randomized controlled trials. *Am J Clin Nutr* **87**, 912–920. Review.
  192. Davey Smith G & Ebrahim S (2003) 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? *Int J Epidemiol* **32**, 1–22.
  193. Botto LD & Yang Q (2000) 5, 10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: a HuGE review. *Am J Epidemiol* **151**, 862–877.
  194. Spittle AJ, Orton J, Doyle LW, *et al.* (2007) Early developmental intervention programs post hospital discharge to prevent motor and cognitive impairments in preterm infants. *The Cochrane Database System Reviews*, **18**(2), CD005495.
  195. Garn H & Renz H (2007) Epidemiological and immunological evidence for the hygiene hypothesis. *Immunobiology* **212**, 441–452.
  196. Kabesch M & Lauener RP (2004) Why Old McDonald had a farm but no allergies: genes, environments, and the hygiene hypothesis. *J Leukoc Biol* **75**, 383–387.
  197. Renz H & Herz U (2002) The bidirectional capacity of bacterial antigens to modulate allergy and asthma. *Eur Respir J* **19**, 158–171.
  198. von Mutius E (2007) Allergies, infections and the hygiene hypothesis – the epidemiological evidence. *Immunobiology* **212**, 433–439.
  199. von Mutius E & Schmid S (2006) The PASTURE project: EU support for the improvement of knowledge about risk factors and preventive factors for atopy in Europe. *Allergy* **61**, 407–413.
  200. Prescott SL, Macaubas C, Smallacombe T, *et al.* (1999) Development of allergen-specific T-cell memory in atopic and normal children. *Lancet* **353**, 196–200.
  201. Szeftalusi Z, Nentwich I, Gerstmayr M, *et al.* (1997) Prenatal allergen contact with milk proteins. *Clin Exp Allergy* **27**, 28–35.
  202. Uthoff H, Spenner A, Reckelkamm W, *et al.* (2003) Critical role of preconceptional immunization for protective and non-pathological specific immunity in murine neonates. *J Immunol* **171**, 3485–3492.
  203. Antohe F, Radulescu L, Gafencu A, *et al.* (2000) Expression of functionally active FcRn and the differentiated bidirectional transport of IgG in human placental endothelial cells. *Hum Immunol* **62**, 93–105.
  204. Gutierrez G, Gentile T, Miranda S, *et al.* (2005) Asymmetric antibodies: a protective arm in pregnancy. In Immunology of Pregnancy. [Markert UR, editor] Karger, *Chem Immunol Allergy* **89**, 158–168.
  205. Szeftalusi Z, Loibichler C, Pichler J, *et al.* (2000) Direct evidence for transplacental allergen transfer. *Pediatr Res* **48**, 404.
  206. Breuer K, Wittmann M, Bosche B, *et al.* (2000) Severe atopic dermatitis is associated with sensitization to staphylococcal enterotoxin B (SEB). *Allergy* **55**, 551–555.
  207. Bunikowski R, Mielke M, Skarabis H, *et al.* (1999) Prevalence and role of serum IgE antibodies to the *Staphylococcus aureus*-derived superantigens SEA and SEB in children with atopic dermatitis. *J Allergy Clin Immunol* **103**, (1 Pt 1), 119–124.
  208. Waser M, Michels KB, Bieli C, *et al.* (2006) Inverse association of farm milk consumption with asthma and allergy in rural and suburban populations across Europe. *Clin Exp Allergy* **37**, 661–670.
  209. Batra A, Pietsch J, Fedke I, *et al.* (2007) Leptin-dependent toll-like receptor expression and responsiveness in pre-adipocytes and adipocytes. *Am J Pathol* **170**, 1931–1941.
  210. Fantuzzi G, Sennello JA, Batra A, *et al.* (2005) Defining the role of T cell-derived leptin in the modulation of hepatic or intestinal inflammation in mice. *Clin Exp Immunol* **142**, 31–38.
  211. Froicu M & Cantorna MT (2007) Vitamin D and the vitamin D receptor are critical for control of the innate immune response to colonic injury. *BMC Immunol* **8**, 1–11.
  212. Reichrath J, Lehmann B, Carlberg C, *et al.* (2006) Vitamins as hormones. *Horm Metab Res* **39**, 71–84.
  213. Blümer N, Sel S, Virna S, *et al.* (2007) Perinatal maternal application of *Lactobacillus rhamnosus* GG suppresses allergic airway inflammation in mouse offspring. *Clin Exp Allergy* **37**, 348–357.
  214. Kalliomaki M, Salminen S, Poussa T, *et al.* (2003) Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial. *Lancet* **361**, 1869–1871.



215. Boehm G, Jelinek J, Knol J, *et al.* (2004) Prebiotics and immune responses. *J Pediatr Gastroenterol Nutr* **39**, Suppl. 3, S772–S773. Review.
216. Wegmann M, Fehrenbach H, Fehrenbach A, *et al.* (2005) Involvement of distal airways in a chronic model of experimental asthma. *Clin Exp Allergy* **35**, 1263–1271.
217. Torgerson C (2001) The effective management of osteoporosis. In *The Economics of Fracture Prevention*, pp. 111–121 [DH Barlow, RM Francis and A Miles, editors].
218. UK coronary Heart Disease Statistics (2009–2010). British Heart Foundation. Resource Code: G30U/0210. Date Published: 15/02/2010. <http://www.bhf.org.uk/publications/view-publication.aspx?ps=1001141>
219. Winsloe C, Earl S, Dennison EM, *et al.* (2009) Early life factors in the pathogenesis of osteoporosis. *Curr Osteoporosis Rep* **7**, 140–144.
220. Tobias JH, Steer CD, Emmett PM, *et al.* (2005) Bone mass in childhood is related to maternal diet in pregnancy. *Osteoporos Int* **16**, 1731–1741.
221. Nguyen TV, Center JR & Eisman JA (2004) Bone mineral density-independent association of quantitative ultrasound measurements and fracture risk in women. *Osteoporos Int* **15**, 942–947.
222. Rauchenzauner M, Schmid A, Heinz-Erian P, *et al.* (2007) Sex- and age-specific reference curves for serum markers of bone turnover in healthy children from 2 months to 18 years. *J Clin Endocrinol Metab* **92**, 443–449.
223. Clark EM, Ness AR, Bishop NJ, *et al.* (2006) Association between bone mass and fractures in children: a prospective cohort study. *J Bone Miner Res* **21**, 1489–1495.
224. Goulding A, Jones IE, Taylor RW, *et al.* (2000) More broken bones: a 4-year double cohort study of young girls with and without distal forearm fractures. *J Bone Miner Res* **15**, 2011–2018.
225. Hernandez CJ, Beaupré GS & Carter DR (2003) A theoretical analysis of the relative influences of peak BMD, age-related bone loss and menopause on the development of osteoporosis. *Osteoporosis Int* **14**, 843–847.
226. Godfrey K, Walker-Bone K, Robinson S, *et al.* (2001) Neonatal bone mass: influence of parental birthweight, maternal smoking, body composition, and activity during pregnancy. *J Bone Miner Res* **16**, 1694–1703.
227. Javaid MK, Godfrey KM, Taylor P, *et al.* (2005) Umbilical cord leptin predicts neonatal bone mass. *Calcif Tissue Int* **76**, 341–347.
228. Javaid MK, Godfrey KM, Taylor P, *et al.* (2004) Umbilical venous IGF-1 concentration, neonatal bone mass, and body composition. *J Bone Miner Res* **19**, 56–63.
229. Cooper C, Fall C, Egger P, *et al.* (1997) Growth in infancy and bone mass in later life. *Ann Rheum Dis* **56**, 17–21.
230. Cooper C, Cawley M, Bhalla A, *et al.* (1995) Childhood growth, physical activity, and peak bone mass in women. *J Bone Miner Res* **10**, 940–947.
231. Jones G & Dwyer T (2000) Birth weight, birth length, and bone density in prepubertal children: evidence for an association that may be mediated by genetic factors. *Calcif Tissue Int* **67**, 304–308.
232. Fewtrell M, Prentice A, Cole TJ, *et al.* (2000) Effects of growth during infancy and childhood on bone mineralization and turnover in preterm children aged 8–12 years. *Acta Paediatr* **89**, 148–153.
233. Fall C, Hindmarsh P, Dennison E, *et al.* (1998) Programming of growth hormone secretion and bone mineral density in elderly men: a hypothesis. *J Clin Endocrinol Metab* **83**, 135–139.
234. Weiler HA, Yuen CK & Seshia MM (2002) Growth and bone mineralization of young adults weighing less than 1500 g at birth. *Early Hum Dev* **67**, 101–112.
235. Javaid MK, Lekamwasam S, Clark J, *et al.* (2006) Infant growth influences proximal femoral geometry in adulthood. *J Bone Miner Res* **21**, 508–512.
236. Cooper C, Eriksson JG, Forsen T, *et al.* (2001) Maternal height, childhood growth and risk of hip fracture in later life: a longitudinal study. *Osteoporos Int* **12**, 623–629.
237. Fewtrell MS, Prentice A, Jones SC, *et al.* (1999) Bone mineralization and turnover in preterm infants at 8–12 years of age: the effect of early diet. *J Bone Miner Res* **14**, 810–820.
238. Fewtrell M, Cole TJ, Bishop NJ, *et al.* (2000) Neonatal factors predicting childhood height in preterm infants: evidence for a persisting effect of early metabolic bone disease? *J Pediatrics* **137**, 668–673.
239. Winzenberg TM, Shaw K, Fryer J, *et al.* (2006) Calcium supplementation for improving bone mineral density in children. *The Cochrane Database System Reviews* issue 2, CD005119.
240. Fuchs RK & Snow CM (2002) Gains in hip bone mass from high-impact training are maintained: a randomized controlled trial in children. *J Pediatr* **141**, 357–362.
241. Specker B, Binkley T & Fahrenwald N (2004) Increased periosteal circumference remains present 12 months after an exercise intervention in preschool children. *Bone* **35**, 1383–1388.
242. Iuliano-Burns S, Saxon L, Naughton G, *et al.* (2003) Regional specificity of exercise and calcium during skeletal growth in girls: a randomized controlled trial. *J Bone Miner Res* **18**, 156–162.
243. Hibbeln JR, Davis JM, Steer C, *et al.* (2007) Maternal seafood consumption in pregnancy and neurodevelopmental outcomes in childhood (ALSPAC study): an observational cohort study. *Lancet* **369**, 578–585.
244. Daniels JL, Longnecker MP, Rowland AS, *et al.* (2004) Fish intake during pregnancy and early cognitive development of offspring. *Epidemiology* **15**, 394–402.
245. Ong KK, Emmett PM, Noble S, *et al.* (2006) Dietary energy intake at the age of 4 months predicts postnatal weight gain and childhood body mass index. *Pediatrics* **117**, e503–e508.
246. Gunnell D, Miller LL, Rogers I, *et al.* (2005) Association of insulin-like growth factor I and insulin-like growth factor-binding protein-3 with intelligence quotient among 8- to 9-year-old children in the Avon Longitudinal Study of Parents and Children. *Pediatrics* **116**, e681–e686.
247. Shaheen SO, Newson RB, Henderson AJ, *et al.* (2005) Prenatal paracetamol exposure and risk of asthma and elevated immunoglobulin E in childhood. *Clin Exp Allergy* **35**, 18–25.
248. Lack G, Fox D, Northstone K, *et al.* (2003) Factors associated with the development of peanut allergy in childhood. *N Engl J Med* **348**, 977–985.
249. Ong KK & Dunger DB (2004) Birth weight, infant growth and insulin resistance. *Eur J Endocrinol* **151**, U131–U139.
250. Gilbert JS, Lang AL, Grant AR, *et al.* (2005) Maternal nutrient restriction in sheep: hypertension, decreased nephron number in offspring at 9 months of age. *J Physiol (London)* **565**, 137–148.
251. Ford SP, Hess BW, Schwobe MM, *et al.* (2007) Maternal undernutrition during early to mid-gestation in the ewe results in altered growth, adiposity, and glucose tolerance in male offspring. *J Anim Sci* **85**, 1285–1294.
252. Cleal JK, Poore KR, Boullin JP, *et al.* (2007) Mismatched pre- and postnatal nutrition leads to cardiovascular dysfunction and altered renal function in adulthood. *PNAS* **104**, 9529–9533.
253. Fewtrell MS, Williams JE, Singhal A, *et al.* (2009) Early diet and peak bone mass: 20 year follow-up of a randomized trial of early diet in infants born preterm. *Bone* **45**, 142–149.